<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Ashish Yadav on Medium]]></title>
        <description><![CDATA[Stories by Ashish Yadav on Medium]]></description>
        <link>https://medium.com/@yadav_ashish?source=rss-7dc613c7b115------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*tp2lEN1pLkcz8cto_6C_Yw.png</url>
            <title>Stories by Ashish Yadav on Medium</title>
            <link>https://medium.com/@yadav_ashish?source=rss-7dc613c7b115------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 23:01:05 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@yadav_ashish/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[The Economics of AI Partnerships in Life Sciences]]></title>
            <link>https://medium.com/@yadav_ashish/the-economics-of-ai-partnerships-in-life-sciences-67db936dc3cc?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/67db936dc3cc</guid>
            <category><![CDATA[healthcare-innovations]]></category>
            <category><![CDATA[ai-in-life-sciences]]></category>
            <category><![CDATA[digital-transformation]]></category>
            <category><![CDATA[ai-strategy]]></category>
            <category><![CDATA[strategic-partnerships]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Fri, 13 Nov 2026 23:31:01 GMT</pubDate>
            <atom:updated>2026-11-13T23:31:01.532Z</atom:updated>
            <content:encoded><![CDATA[<p>A life sciences AI partnership commits more than a technology budget. It can change which decisions a company makes internally, which knowledge it obtains from a provider, and how difficult it becomes to operate without that provider. The economic case needs to account for those changes before the organization treats a pilot as a strategic capability.</p><p>Announcements make the ambition visible. They rarely make the full operating cost visible. Model access, cloud infrastructure, integration, domain review, validation, and workforce changes appear in different budgets. A partnership can look attractive in procurement while creating substantial work for the clinical, scientific, quality, and data teams that have to make it usable.</p><p>My perspective comes from regulated product development, partnerships, and data and AI strategy. I assess an arrangement by the capability it leaves inside the organization: whether people can evaluate results, understand the evidence, improve the workflow, and change course when a provider or use case no longer fits.</p><p>The first investment should therefore be tied to a defined workflow and a credible baseline. Without those, the enterprise can buy access to powerful technology and still lack a defensible account of what improved.</p><p>Microsoft and Haleon announced a multiyear collaboration spanning consumer insights, R&amp;D, supply chain, and other operations. IQVIA described a relationship with AWS around an agentic platform for clinical and healthcare work. Anthropic and the Gates Foundation described a commitment across global health, life sciences, and other areas. These announcements are not directly comparable deals. They show how broadly the word “partnership” is now used. [1–3]</p><p>The arrangements differ in purpose and contribution. Their stated ambitions are useful context, but an announcement cannot establish realized return for an individual customer. The economic assessment has to move to the workflow and the organization implementing it.</p><h3>Begin with the unit of value</h3><p>An organization may say that an AI partnership will accelerate research, improve clinical operations, or increase productivity. Those aspirations are too broad to evaluate. The unit of value should be a decision or process with a baseline.</p><p>In clinical development, an AI tool might reduce the time to identify potentially eligible patients. The economic benefit is not the number of matches generated. It depends on how many are confirmed, whether enrollment improves, how much staff review is required, and whether the tool helps reach patients the existing process missed. A fast system that produces a large number of false leads may shift work rather than remove it.</p><p>In medical, legal, and regulatory review, a system might prepare evidence, flag possible unsupported claims, and route content. Time saved in initial review has value only if the process does not create more rework, inconsistent decisions, or a weakened record of why material was approved.</p><p>In discovery, a model might prioritize experiments. Its value lies in the quality of the experimental portfolio and the learning gained per unit of time and cost. Counting generated hypotheses does not tell management whether more promising programs are moving forward.</p><p>Define the baseline before the pilot. What does the current process cost in people, elapsed time, errors, delays, and missed opportunities? What would a meaningful improvement look like? Which costs will be added for data preparation, integration, validation, monitoring, and change management? If the organization cannot answer those questions, a pilot can succeed on a demonstration metric while the investment case remains unknown.</p><h3>Separate access from capability</h3><p>A technology provider can supply models, infrastructure, development tools, and support. That gives an enterprise access to capabilities it might be uneconomic to build internally. Access is valuable, but it is not the same as the enterprise’s own ability to identify good use cases, prepare data, evaluate results, redesign work, and intervene when a system fails.</p><p>A life sciences company should retain people who understand its clinical, scientific, regulatory, and operational decisions. Those people need enough technical fluency to challenge a vendor proposal. They do not all need to become model engineers. They do need to know when a measure is poorly defined, when data from a later point have entered a retrospective evaluation, or when a claimed benefit has been measured against an unrealistic baseline.</p><p>This is especially important when a partner brings a ready-made application. A polished product can conceal assumptions about a workflow. A site-feasibility tool may use a definition of enrollment that differs from the sponsor’s. A scientific search agent may retrieve approved documents but miss a later amendment. A content-review agent may cite a sentence without understanding the intended claim in its full context.</p><p>The enterprise’s own capability is the ability to recognize and correct such gaps. A partnership that leaves the company unable to do that may increase short-term speed while creating a long-term dependency.</p><h3>Count the integration cost honestly</h3><p>The cost of an AI application is rarely the model fee alone. There may be data cleanup, system integration, identity and access controls, validation, user training, vendor oversight, monitoring, record retention, security review, and internal product management. Some of these costs recur whenever the workflow, model, or underlying data source changes.</p><p>The costs also appear in other teams’ time. A clinical expert reviewing model output, a statistician designing an evaluation, a quality team assessing a change, and a data engineer reconciling source systems all contribute to the product. If their work is treated as free, the return calculation will look better than the operating reality.</p><p>Variable usage costs can matter at scale. A prototype may process a small set of documents. A deployed service may process millions of records, use several model calls per task, and retain traces for review. The organization should model the complete unit cost at realistic volume, including retries and human review.</p><p>Conversely, a pilot may have high initial cost and strong long-term economics if its data and workflow foundations can be reused. The investment case should distinguish one-time infrastructure from recurring service costs and reusable capability. Claiming all foundational work as a cost of the first use case can kill a good portfolio; spreading a bespoke integration across imagined future use cases can make a weak one look attractive.</p><p>Both errors can be avoided with explicit assumptions.</p><h3>Build buy and partner are choices about control</h3><p>The familiar build-versus-buy discussion is incomplete for AI because most applications combine internal and external components. A company might use a cloud provider’s infrastructure, a foundation model from another provider, an external vendor’s orchestration layer, and internal clinical data and review processes. “Build” may still mean building the workflow and evaluation while buying the model.</p><p>Control should be assessed at the component level. Who owns the data and derived features? Who can change the prompt or workflow? Can the organization inspect and test model behavior? Who decides when a provider update reaches production? Can the application be moved to another model or platform? What happens to configured knowledge and evaluation records if the agreement ends?</p><p>Some capabilities should remain internal because they embody the company’s scientific judgment or regulated responsibility. Other components are widely available and can be sourced competitively. A strategic partnership may be appropriate when both parties must contribute expertise over time and share the uncertainty of developing a new application.</p><p>No single answer fits every use case. The point is to decide deliberately what is proprietary, what is replaceable, and what must be jointly developed.</p><h3>Switching costs are created during implementation</h3><p>Vendor lock-in is often discussed as a contract issue. Much of it is built through architecture and everyday work. If a clinical workflow is configured around one provider’s proprietary data structures, prompts, agent tools, and user interface, changing providers may require more than exporting files. Staff must relearn the process. Evaluations may need to be rerun. Records retained in one system may be difficult to reconstruct. Integrations with source systems and permissions may need rebuilding.</p><p>The answer is not to insist that every component be portable at any cost. Portability can add complexity and reduce the benefit of a tightly integrated solution. Leadership should understand the tradeoff and price it into the decision.</p><p>An exit plan can be simple and concrete. Identify the data and configurations the company can export, the format, the expected effort to move, the treatment of historical evidence, and the minimum service continuity required during transition. Test the most important assumptions before they become contractual abstractions.</p><p>Vendor concentration may be acceptable for a bounded, lower-impact use case. It deserves greater attention when the application supports a core clinical, manufacturing, or regulatory process. The consequence of interruption should set the required continuity standard.</p><h3>Partnership governance should follow the use cases</h3><p>A single enterprise AI committee cannot review every change to every application. Nor can each team develop its own rules in isolation. The operating model should combine common standards with decision-specific oversight.</p><p>Common standards may cover security, privacy, access, source traceability, model and workflow versioning, incident reporting, and procurement terms. A specific application then needs an owner, a defined use, a tailored evaluation, monitoring thresholds, and a route for escalation.</p><p>For example, an internal drafting assistant may need strong confidentiality and source controls but a different clinical evidence package from an AI-enabled diagnostic. A trial matching system needs attention to missed eligible patients and site workflow. An agent that initiates actions across systems needs clear boundaries on what it may do without human approval.</p><p>The partnership agreement should support those distinctions. It should specify notification of changes that may affect a regulated or consequential workflow, access to information needed for evaluation, incident cooperation, and responsibilities when a tool interacts with third-party systems. A generic promise of “responsible AI” is not an operating model.</p><p>In a sponsor–CRO–technology arrangement, responsibility spans more than two parties. The sponsor remains responsible for its program decisions, the CRO operates delegated processes, and the technology provider may control important software. The handoffs among them should be designed before automation scales.</p><h3>A portfolio needs stop rules</h3><p>Large AI partnerships often generate more proposed use cases than an organization can properly develop. The portfolio then becomes a list of pilots, each with a sponsor and an optimistic value estimate. Some never reach production, but they continue to absorb data and subject matter expert time.</p><p>Each use case needs an investment gate. First, define the decision and baseline. Next, test technical feasibility and data suitability. Then evaluate real workflow performance in a limited setting. Scale only if the outcome, risk, and economics remain credible. At each stage, name a reason to stop or redesign.</p><p>A stop rule preserves resources for applications that have a stronger evidence and economic case. A partnership that makes it politically difficult to end a weak pilot has introduced a hidden cost.</p><p>Portfolio measures should include adoption by the right users, decisions improved, quality or safety outcomes, time and cost, and internal capability gained. Usage counts and generated outputs are useful diagnostics, but they are not the final value measure.</p><p>Novartis’s public account of board oversight illustrates the range of AI questions that can reach directors: applications across discovery and development, risk classification, data management, human capital, and strategic opportunity. A board need not choose models. It should understand whether management can distinguish experimentation from material dependence and whether investment is producing capability that endures. [4]</p><h3>The economics of learning</h3><p>Some AI investments will have uncertain direct returns yet still create valuable learning. A well-designed pilot can reveal poor data quality, an inefficient workflow, or an unmet user need. That learning has value if it changes the next decision.</p><p>The distinction is between learning deliberately and continuing indefinitely. An experiment should state what uncertainty it will resolve and what the organization will do with the answer. If a pilot finds that a model performs well but the data arrive too late, the next investment may be in the data flow. If users rarely accept a recommendation, the team should investigate the workflow before purchasing more model capacity.</p><p>Partnerships can accelerate that learning when providers bring technical expertise and customers bring domain context. They can also produce superficial activity if neither party has a mechanism to convert observations into changes.</p><p>For a smaller biotech, a partner can provide access to expertise that would be difficult to hire. The company still needs an internal owner who can set priorities and preserve the knowledge gained. For a large pharma company, internal scale does not remove the need for partners, but it can support stronger architecture, evaluation, and negotiation capability.</p><p>The economic model should reflect the organization as it is, not the one imagined in a strategy presentation.</p><h3>A decision framework for leadership</h3><p>Before entering or expanding an AI partnership, leadership should resolve seven questions:</p><p>1. Which measurable decision or workflow is the first use case meant to improve?</p><p>2. What is the current baseline, including staff time, errors, delay, and opportunity cost?</p><p>3. Which components and expertise must the enterprise retain internally?</p><p>4. What are the full costs of integration, validation, monitoring, and change?</p><p>5. Which data, workflows, and records can be moved if the relationship changes?</p><p>6. How will both parties manage updates, incidents, and new uses?</p><p>7. What evidence will trigger a scale, redesign, or stop decision?</p><p>The answers need not be perfect at contract signing. They should be specific enough to make the first investment testable and the long-term relationship governable. The investment earns its strategic label when the organization can demonstrate improvement and retain the expertise needed to sustain it. A company should be able to explain the workflow benefit, the full cost of obtaining it, and the dependency it has accepted.</p><p>That account belongs in the partnership review alongside contractual milestones. It gives leadership a defensible basis for renewal, expansion, or exit, rather than requiring the original announcement to serve as the continuing business case.</p><h3>Sources</h3><p>[1] Microsoft. <em>Haleon to accelerate AI-powered transformation with new five-year Microsoft collaboration</em> (June 29, 2026). <a href="https://ukstories.microsoft.com/features/haleon-to-accelerate-ai-powered-transformation-with-new-five-year-microsoft-collaboration/">Source</a></p><p>[2] IQVIA. <em>Strategic collaboration with AWS naming AWS preferred agentic cloud provider</em> (2025). <a href="https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Announces-Strategic-Collaboration-with-AWS-Naming-AWS-as-Preferred-Agentic-Cloud-Provider-to-Power-Next-Generation-AI-Platform/default.aspx">Source</a></p><p>[3] Anthropic. <em>Partnership with the Gates Foundation</em> (May 14, 2026). <a href="https://www.anthropic.com/news/gates-foundation-partnership">Source</a></p><p>[4] Novartis. <em>Q4 2025 Impact and Sustainability Update to Investors</em> (2026), p. 14. <a href="https://www.novartis.com/sites/novartis_com/files/novartis-q4-2025-impact-and-sustainability-update.pdf">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=67db936dc3cc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Turning AI Governance Frameworks into Product Decisions in Life Sciences]]></title>
            <link>https://medium.com/@yadav_ashish/turning-ai-governance-frameworks-into-product-decisions-in-life-sciences-00b77baf7d28?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/00b77baf7d28</guid>
            <category><![CDATA[responsible-ai]]></category>
            <category><![CDATA[medical-devices]]></category>
            <category><![CDATA[life-sciences]]></category>
            <category><![CDATA[data-governance]]></category>
            <category><![CDATA[ai-governance]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Tue, 10 Nov 2026 13:21:01 GMT</pubDate>
            <atom:updated>2026-11-10T13:21:01.442Z</atom:updated>
            <content:encoded><![CDATA[<p>An AI governance policy becomes useful when it changes a product decision. It may limit the population in which a tool is used, require better source controls, prevent an unsupported claim, or allow a well-evaluated application to proceed. A completed checklist cannot demonstrate any of those outcomes on its own.</p><p>Life sciences organizations already have experience making consequential decisions under uncertainty. Clinical development, diagnostic validation, quality systems, and regulatory strategy require evidence that fits a particular use. AI governance should connect to that discipline rather than operate as a separate vocabulary of principles.</p><p>My work across oncology, diagnostics, devices, and partnerships has taught me to look for the operational detail behind a policy. Who owns the output? Can the source and version be reconstructed? Can a qualified person challenge it before action? Who can pause the function when the input fails? These questions identify whether the controls are usable.</p><p>The method below treats governance as a sequence of product decisions with accountable owners. A framework organizes the review; the application’s data, users, evidence, and consequences determine the answer.</p><h3>Begin with the intended decision</h3><p>The team should write a short intended-use statement in plain language. Who uses the tool? What input does it accept? What output does it produce? What action may follow? In which population, setting, and time frame? What is outside scope? This exercise is more useful than classifying the tool as simply “AI in healthcare.”</p><p>Compare three systems. One summarizes publicly available research for an internal scientist. Another ranks possible trial sites for a study team. A third recommends a clinical intervention for a patient. They may share a model provider, but their data, error costs, users, and regulatory questions differ. A single review checklist cannot substitute for an analysis of each intended use.</p><p>The intended-use statement should distinguish advice from automation. “Human in the loop” is too vague. Does the user review every output before action? Can the system prefill a document that is later approved? Does an alert trigger a clinical protocol before anyone checks its basis? The meaning of oversight depends on timing and authority.</p><p>NIST’s AI Risk Management Framework uses functions such as govern, map, measure, and manage. I find it helpful as a structure for these conversations. It is voluntary and broad. The team still needs to translate each function into product-specific evidence and control. [1]</p><p>Microsoft’s Dragon Copilot documentation describes draft generation for clinician review. This published boundary is useful when discussing governance: assessment of a draft assistant should not be represented as evidence for an autonomous clinical decision system. The permitted output, reviewer action, and point of transfer into the clinical record all belong in the use statement. An organization that expands the workflow has to reassess the new reliance it is asking users to place on the system. [4]</p><h3>Map claims to evidence</h3><p>The product team should list every consequential claim it intends to make. “Finds relevant studies” differs from “identifies eligible patients.” “Drafts a summary” differs from “produces an approved medical response.” Each claim needs a population, performance measure, evaluation dataset, comparator, and known limitations.</p><p>For a clinical trial operations model, define a decision baseline and test whether the tool improves a relevant outcome prospectively or in a credible retrospective simulation. For a medical content assistant, evaluate source fidelity, omissions, unsupported claims, review burden, and version traceability. For a patient-facing device function, the applicable clinical, quality, and regulatory evidence may be substantially more demanding.</p><p>The test set should reflect the actual inputs, including incomplete and difficult cases. An evaluation on polished examples may miss the errors that matter in routine work. The team should state which groups and contexts are underrepresented. It should avoid claiming broad reliability from a narrow validation sample.</p><p>Evidence can be staged. An exploratory prototype may justify a controlled pilot. A pilot may justify a broader deployment after performance and workflow are assessed. The gate between stages should be written in advance. This reduces the temptation to redefine success after seeing favorable results.</p><h3>Assign owners to data and outputs</h3><p>Data governance and AI governance intersect at every consequential input. Document the source, permission, provenance, quality expectations, retention, and permitted use of each dataset. If the system retrieves regulated or confidential documents, access controls must apply to both the source and generated answer. A model should not make a restricted document available to a broader user through a friendly interface.</p><p>The output needs ownership too. Who checks it before use? Where is it recorded? Can a user correct it, and does that correction alter the system? Who decides whether an output is an incident? A vendor may own the model service while the life sciences company owns the regulated decision. The boundary must be explicit in contracts and operating procedures.</p><p>Keep a trace linking a consequential output to source data, prompt or configuration where relevant, model version, retrieval index, and human action. The detail varies by use case, but the ability to reconstruct what happened is essential to investigation and learning.</p><p>Privacy and security review should be tied to actual data flows. Is personal information sent to a third-party service? Is it retained? Can it be used to train a general model? Where does it reside, and who can access logs? Generic assurances are less useful than a diagram and an enforceable agreement describing those flows.</p><h3>Decide what a human must do</h3><p>Human oversight is not a safety control merely because a person can see the output. The person needs time, expertise, context, and authority to challenge it. If reviewers face hundreds of fluent drafts under a tight deadline, they may miss an unsupported claim. If clinicians receive an alert with no source context, they may ignore it or accept it uncritically.</p><p>Test the review process itself. Measure errors detected, errors missed, time spent, disagreement between reviewers, and whether the tool changes the user’s decision. The evaluation should include cases where the AI is wrong but persuasive. It should ask whether the user can access the underlying evidence easily enough to make an independent judgment.</p><p>For some uses, a human approval step may be essential. For others, an automated integrity check and periodic sampling may be appropriate. The choice should be proportional to the consequence of error and the reversibility of the action. A blanket rule that every AI output requires sign-off can create ceremonial review; a blanket rule that experts remain accountable without giving them workable controls is equally weak.</p><p>The product should make uncertainty usable. It may abstain when inputs are outside scope, flag missing data, show source passages, or route a case to a specialist. A confident answer when the system has no relevant evidence is a design failure, not simply a user training issue.</p><h3>Govern change over the lifecycle</h3><p>Models, data feeds, clinical practice, and source documents change. Define which changes require a new evaluation, who approves them, and how affected users are told. A minor interface adjustment and a new model version that changes outputs should not pass through identical review, but neither should occur invisibly.</p><p>For a medical device software function, applicable FDA guidance and quality system requirements shape the change process. FDA’s guidance on predetermined change control plans for AI-enabled device software functions offers a product-specific route for planned modifications under its scope. For AI used to support regulatory decision making in drug or biologic development, FDA’s draft framework discusses a risk-based credibility assessment tied to context of use. These documents address different domains; the team should not treat them as one universal approval route. [2, 3]</p><p>Maintain a change log with the reason, affected population and workflow, test evidence, approval, deployment date, and rollback plan. Predictions or outputs should remain linked to the version that generated them. Monitoring should cover data integrity, performance where outcomes are observable, user behavior, and incidents.</p><p>The team needs a pause mechanism. If a source feed breaks or a serious error pattern emerges, who can stop the function, how is work handled meanwhile, and how are affected users informed? A rollback plan written only for a technical outage does not answer a clinical or regulatory incident.</p><h3>Make fairness specific</h3><p>Fairness is often treated as a mandatory metric selected before the use case is known. Start by identifying who might be excluded or harmed by the tool’s data and workflow. In a trial planning system, historical site data may disadvantage newer sites or communities underrepresented in prior studies. In a clinical model, performance and access to follow-up action may differ across patient groups.</p><p>The analysis should include data coverage, error rates where estimation is credible, and the consequences of errors. Small subgroup samples need uncertainty and careful interpretation. A statistically similar score distribution does not prove equitable outcomes if some patients cannot access the intervention the score triggers.</p><p>There may be tradeoffs. Expanding a tool to a population with limited validation could improve access or expose people to poorly understood error. Governance should make the tradeoff explicit and define an evidence plan, rather than claim that one aggregate fairness number settles the matter.</p><p>Patient and clinician input can reveal harms a dataset cannot show: confusing explanations, burdensome follow-up, or a pathway that works only at well-resourced centers. These perspectives should influence product design before broad deployment.</p><h3>Create a decision record not a ceremony</h3><p>For each use case, maintain a compact decision record: intended use and exclusions; data and permissions; key harms and benefits; evidence and uncertainty; human controls; monitoring and change plan; owners; and the decision to pilot, deploy, restrict, or stop. The record should link to detailed technical documentation without forcing executives to read a hundred-page packet for every choice.</p><p>A cross-functional group should challenge the record in proportion to risk. Clinical, regulatory, quality, privacy, security, data, and product specialists may all be needed for a consequential use. A low-risk internal research aid can move through a lighter path. This is risk-based governance in practice: more scrutiny where a wrong output can do more harm.</p><p>Reviewers should identify the weakest assumption, not merely check that each box contains text. Is the evaluation population representative? Is the user actually able to override the recommendation? Can the vendor explain a change? Does the data agreement permit the proposed use? The unresolved assumptions should determine conditions for a pilot or deployment.</p><p>The decision record should be updated when the use changes. A tool introduced to summarize documents may later be used to recommend an action. That is a new context of use even if the underlying model is unchanged. Governance must follow the product’s actual behavior, not its original procurement label.</p><h3>An illustrative product review</h3><p>Imagine a biotechnology company proposes an assistant that drafts responses to medical information questions using approved source documents. The intended user is a trained medical information specialist. The output is a draft, never a direct message to a clinician or patient. The assistant retrieves versioned sources, shows citations, and logs edits before approval.</p><p>The evaluation would include common and difficult questions, outdated sources, ambiguous requests, and cases requiring escalation. The measures would include factual accuracy, source support, omissions, reviewer time, and errors that survive review. Access controls would prevent retrieval of materials outside a user’s role. A change to the model or approved document corpus would trigger defined checks.</p><p>Suppose the pilot saves drafting time but reviewers spend more time verifying citations and a few unsupported statements survive. The governance decision should not be “the model passed because it is accurate on average.” The team might narrow scope, improve retrieval, require abstention for certain questions, and run another evaluation. That is a product decision grounded in evidence.</p><p>If the organization later wants to send answers automatically, the intended use changes dramatically. The earlier pilot does not validate the new workflow. The oversight, evidence, and regulatory or legal assessment must be revisited. This is the practical value of documenting the boundary at the start.</p><h3>What leaders should ask each quarter</h3><p>The quarterly review should establish how many systems are operating, what decisions they influence, who owns them, and whether their current use matches the approved scope. Review incidents, data or model changes, performance signals, user feedback, and overdue mitigations. Identify deployments that were stopped or narrowed because evidence failed to support expansion.</p><p>The last question matters. If governance never changes a product decision, it may be a reporting exercise. A healthy program can approve useful tools, improve weak ones, and say no when risk or evidence warrants it. It can explain those decisions without hiding behind generic principles.</p><p>A governance framework earns its place when the company can show how it influenced a consequential use. That account should connect the evidence to the permitted action, the remaining uncertainty, and the person responsible for reassessment. It allows management to advance a useful application without claiming that the framework itself proves the application safe or effective.</p><p>A useful test of governance maturity is whether a team can explain a proposal it declined or narrowed. A record of a promising system that was narrowed because the evidence did not support a broader population demonstrates that the review has influence. It also gives the team a path to revisit the decision when better data become available. Governance should help useful products advance under the right conditions and keep unsupported claims from becoming routine practice.</p><h3>Sources</h3><p>[1] National Institute of Standards and Technology. <em>AI Risk Management Framework.</em> <a href="https://www.nist.gov/itl/ai-risk-management-framework">Source</a></p><p>[2] U.S. Food and Drug Administration. <em>Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products</em> (draft guidance, 2025). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological">Source</a></p><p>[3] U.S. Food and Drug Administration. <em>Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions</em> (final guidance, 2025). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence">Source</a></p><p>[4] Microsoft. What is Microsoft Dragon Copilot (physicians)? <a href="https://learn.microsoft.com/en-us/industry/healthcare/dragon-copilot/about/">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=00b77baf7d28" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What a Biotech Data Platform Actually Costs]]></title>
            <link>https://medium.com/@yadav_ashish/what-a-biotech-data-platform-actually-costs-c9cac02000c0?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/c9cac02000c0</guid>
            <category><![CDATA[data-platforms]]></category>
            <category><![CDATA[finops]]></category>
            <category><![CDATA[life-sciences]]></category>
            <category><![CDATA[clinical-data]]></category>
            <category><![CDATA[biotech]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Thu, 05 Nov 2026 11:56:01 GMT</pubDate>
            <atom:updated>2026-11-05T11:56:01.528Z</atom:updated>
            <content:encoded><![CDATA[<p>The cloud invoice is only one part of a biotech data platform’s cost. A company also pays for reconciliation, source-system changes, domain expertise, validation, support, and the time its teams spend deciding which result is reliable. A cheaper architecture can leave those costs untouched.</p><p>The business case should follow the work. Can the clinical team investigate an enrollment problem sooner? Can a scientist connect a result to the correct specimen and assay version? Can an analyst reproduce a consequential figure without rebuilding the chain of evidence? These questions make the investment specific enough to evaluate.</p><p>My experience across clinical development, diagnostics, and regulated product strategy has made me cautious about counting data availability as business value. Files can be accessible while definitions remain disputed and the decision process still depends on manual reconciliation. The platform has created storage capacity; the organization has yet to obtain the capability it was funding.</p><p>A useful cost model therefore joins direct technology spending to the labor, delay, and control requirements of a defined workflow. It should show which costs are incurred initially, which recur, and which genuinely fall when another application reuses the foundation.</p><h3>Define the portfolio of decisions</h3><p>Begin with a small set of recurring decisions rather than a general mandate to “centralize data.” One might be whether a trial needs recruitment intervention. Another might be whether a biomarker assay is ready for a planned analysis. A third might be whether a safety signal warrants review. Each requires specific data, freshness, lineage, access, and people.</p><p>The platform does not need every dataset on day one. It needs reliable pathways for the selected decisions. A raw landing zone can be useful, but a team cannot act merely because files are stored together. The work of identity resolution, semantic definitions, quality checks, and governed access determines whether the data can be trusted.</p><p>Document the current process: systems queried, manual exports, spreadsheets, review cycles, rework, and elapsed time. This baseline makes the investment measurable. It also reveals whether a bottleneck is technical or organizational. If teams disagree on what “active site” means, a faster warehouse query will return the disagreement sooner, not resolve it.</p><p>The platform’s value may come from avoiding a costly error rather than accelerating a routine report. That is harder to quantify but should not be ignored. A mislabeled assay version or an outdated clinical extract can compromise an analysis. The case should distinguish defensible risk reduction from speculative claims that every future AI project will generate revenue.</p><p>Snowflake’s cost documentation separates compute, storage, and data transfer and notes that some features have additional cost behavior. That is a useful starting point for technical costing. A biotech investment review still needs the work outside those categories: reconciling source data, maintaining definitions, reviewing access, reproducing analyses, and supporting users. The vendor’s consumption model explains part of the invoice; it does not supply the organization’s complete cost of producing usable evidence. [4]</p><h3>Count build and run costs separately</h3><p>Initial costs include architecture, ingestion, migration, security design, data modeling, validation, and change management. Running costs include compute, storage, network transfer, monitoring, support, data quality triage, access reviews, vendor fees, and periodic revalidation. People costs span platform engineers, stewards, clinical data experts, analysts, and quality or compliance specialists.</p><p>Compute is workload dependent. A batch pipeline, an interactive analytics environment, and a machine learning training job have different patterns. A platform can incur idle clusters, duplicate environments, excessive data movement, or expensive queries created by poor modeling. Cost allocation should make those patterns visible to the teams that can change them.</p><p>Include the cost of parallel legacy systems during transition. A biotech cannot always retire an established clinical system simply because a new analytical environment exists. The migration period may increase spending before it saves anything. A plan that assumes immediate decommissioning can make the return on investment look better than reality.</p><p>Contracts and data egress deserve attention. Switching platforms may require extracting large volumes, rebuilding transformations, and revalidating workflows. That cost is not an argument against a vendor; it is a reason to preserve portable formats, clear ownership of transformations, and a documented exit path.</p><h3>The expensive work is often semantic</h3><p>Clinical, laboratory, imaging, manufacturing, and commercial data describe different parts of a product journey. The same patient, specimen, site, or product may carry different identifiers across systems. Dates can refer to collection, processing, receipt, entry, or approval. A platform that joins these records without understanding their meaning can create confident but wrong answers.</p><p>Budget for domain stewards who can define data contracts and resolve ambiguity. A clinical operations expert may know why a site status changed; a laboratory expert may know what a failed assay run means; a statistician may know which analysis population is relevant. These people are not overhead to remove once the architecture is installed. They support the controls needed for the platform’s defined use.</p><p>Versioning is another cost with clear value. A trial protocol, assay, data transformation, and analysis plan can change. Reproducibility requires preserving which versions generated a result. If a new platform overwrites data and transformation logic without a usable history, it may make current dashboards fast while making regulatory reconstruction painful.</p><p>Separate data ingestion from data readiness. A dataset is “available” when files arrived. It is “decision ready” when definitions, provenance, quality, permissions, and intended use are clear. Reporting the first as the second inflates progress.</p><p>FDA’s clinical electronic source and electronic systems guidance help establish why reliable records and traceability belong in the cost case. Their relevance depends on the platform’s intended clinical use. An exploratory environment and a system relied on for regulated clinical records should not be assigned identical assurance requirements without assessing their role. [2, 3]</p><h3>Measure value at the workflow level</h3><p>A platform team may report terabytes ingested, number of pipelines, or number of users. Those are operating measures, not business outcomes. Pair them with the workflows the investment was meant to improve: time to reconcile enrollment, time to produce a validated analysis dataset, number of repeated manual mappings, time to investigate a quality issue, and frequency of avoidable rework.</p><p>The measure should include the whole process. If a dashboard refreshes in minutes but an analyst spends two days checking whether the source is complete, the decision cycle has not shrunk to minutes. If a self-service tool shifts support work to scientists who lack data engineering training, the labor did not disappear.</p><p>Compare cohorts of work before and after implementation, while accounting for changes in study complexity and staffing. An apparent improvement may result from a simpler project mix. A credible value story explains the baseline, the intervention, and the plausible contribution of the platform.</p><p>The most valuable outcome may be a better decision. A team might intervene earlier at a struggling site or detect a specimen backlog before a biomarker analysis is delayed. Such cases should be documented with enough detail to distinguish platform contribution from normal expert judgment. A story is useful evidence of mechanism; it is not a substitute for a portfolio-level measure.</p><h3>Build in increments with explicit gates</h3><p>Fund an initial product around one cross-functional workflow. For example, clinical operations could integrate site activation, enrollment, and data quality signals for one program. The gate to expand would require reliable source feeds, accepted definitions, active use by the decision owners, and demonstrated reduction in a specified delay or rework measure.</p><p>The second workflow should reuse part of the foundation, such as identity management, lineage, and governance. If every new use case requires bespoke integration and a separate team, the platform is not yet creating economies of scope. Conversely, insisting on a universal canonical model before any workflow is useful can consume years. The architecture should be modular enough to learn.</p><p>Stop rules matter. A data source with unstable access or poor quality may make a proposed use case uneconomic. The team can defer that integration and select a different question. A platform strategy is stronger when it can say no to low-value ingestion.</p><p>FinOps practices can help track and allocate cloud spending, but cost optimization should not be reduced to turning off compute. A cheaper pipeline that fails silently or delays a clinical review is expensive in another budget. The goal is cost per reliable decision, with controls proportionate to the risk. [1]</p><h3>AI changes the economics but does not erase them</h3><p>Generative AI can make unstructured documents easier to search or summarize. It can also add model fees, retrieval infrastructure, evaluation, human review, security, and monitoring. A platform built for analytics may need new controls for prompts, source citations, access boundaries, and model versions. Those costs should be attached to a real use case.</p><p>The value of an AI assistant depends on the source material. If trial documents have inconsistent names, poor metadata, or unclear ownership, a polished answer can make the underlying problem harder to see. Investing in provenance and document controls may be more valuable than adding another interface.</p><p>Measure the combined workflow. For a medical review assistant, how much time do reviewers spend finding, checking, correcting, and approving an answer? What errors appear? Can the source and version be reconstructed? The business case should include expert review even if the draft is produced almost instantly.</p><p>There may be a positive spillover: better data contracts and lineage developed for one AI use case can improve conventional analytics and audits. That benefit is real when demonstrated, but it should not be counted twice across projects.</p><h3>A finance conversation worth having</h3><p>Finance, technology, data, quality, and business owners need a shared account of the investment. The platform team can describe direct spending and service levels. Domain teams can describe manual effort and decision delays. Finance can test assumptions about avoided cost and timing. Quality and regulatory colleagues can identify controls that cannot be removed to improve an apparent return.</p><p>The discussion should use ranges where estimates are uncertain. A base case might assume modest adoption and slower retirement of legacy processes. An upside case might show what happens when a second and third workflow reuse the foundation. A downside case might include integration delays or higher review effort. The point is to understand what drives the result, not to produce a precise-looking number.</p><p>An internal chargeback model can encourage responsible use, but it can also discourage research teams from exploring legitimate questions if every query feels expensive. Make costs visible first, then choose incentives that fit the organization’s stage. A small biotech with one pivotal program has a different risk appetite from a diversified pharmaceutical company.</p><p>The unit of value should remain a reliable decision, not a gigabyte. This reframes conversations about architecture. A design that costs more to run but substantially improves traceability and reduces rework may be the better economic choice. A cheaper design may be appropriate for exploratory work with lower consequences.</p><h3>Questions for a quarterly review</h3><p>The quarterly review should examine which decisions improved, which data assets were reused, which manual steps disappeared, and which new support burdens appeared. Review cost by workload and owner, pipeline reliability, quality incidents, access requests, and the time needed to reproduce a consequential analysis. Assess whether the next use case can be delivered faster because the foundation exists.</p><p>The review also needs a retirement plan. Old reports, duplicate extracts, and unused environments accumulate. A platform can become a new layer of expense if the organization never decommissions the old ways of working. Retirement requires confidence, communication, and often a period of parallel validation. It should be planned as carefully as launch.</p><p>The review should end with a funding decision: expand, stabilize, narrow, or stop a component. Technology investments become durable when leaders can explain the evidence for the next increment.</p><h3>The economic principle</h3><p>A biotech data platform succeeds when it lowers the total cost of producing and acting on trustworthy evidence. Cloud architecture can help, but the value is realized in clinical, scientific, and operational workflows. It depends on data meaning, lineage, people, and disciplined scope.</p><p>Hypothetical future AI applications are insufficient justification for the platform, while a cost review confined to cloud spending misses much of its economic effect. The right accounting joins direct spending to the labor, delay, and risk embedded in today’s decisions. Once those are visible, the company can invest in the parts of the platform that actually change its work.</p><h3>A worked decision example</h3><p>Consider a hypothetical life sciences organization with several development programs. Each week, its planning team combines partner reports, operational trackers, and internal forecasts. Staff spend substantial time reconciling identifiers and dates before a program meeting. A proposed platform promises a more frequent integrated view.</p><p>First verify the baseline: how many hours are spent, how often the numbers disagree, which disagreements affect decisions, and how quickly a meaningful recruitment problem is detected. Then price the integration, stewardship, support, validation, and ongoing cloud usage. The platform may save manual preparation and enable earlier intervention. It may also create a new burden when source systems change. Both belong in the case.</p><p>After a pilot, assess whether the program team acted earlier on a site problem and whether the resulting action plausibly changed a milestone. If meetings simply move from arguing over spreadsheets to arguing over dashboard definitions, the platform has not solved the key issue. The next investment may need to be a shared data contract with the CRO rather than more compute.</p><p>A simplified planning calculation makes the distinction concrete. Suppose a workflow releases 20 staff hours per week and the company values those hours at an assumed loaded rate of $100. Over 50 working weeks, that is $100,000 of capacity value. It is not automatically $100,000 of cash savings. If annual platform and support costs are $120,000, the labor estimate alone does not cover them. The case needs additional demonstrated value or a lower-cost design. These are illustrative assumptions, not industry benchmarks.</p><p>Now imagine the same foundation supports another evidence workflow. Reused identifiers, lineage, access controls, and operational definitions lower the marginal cost of that second application. That is where platform economics can become attractive. The return should show the reuse explicitly rather than attribute all benefits to the first dashboard.</p><p>This hypothetical example shows why the return depends on sequencing and adoption. The investment case should distinguish time released for other work from cash expense actually removed, and a plausible contribution to a milestone from evidence that the platform caused it. Those distinctions make the economics credible enough to guide the next funding decision.</p><h3>Sources</h3><p>[1] FinOps Foundation. <em>FinOps Framework.</em> <a href="https://www.finops.org/framework/">Source</a></p><p>[2] U.S. Food and Drug Administration. <em>Electronic Source Data in Clinical Investigations</em> (2013). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-source-data-clinical-investigations">Source</a></p><p>[3] U.S. Food and Drug Administration. <em>Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers</em> (final guidance, October 2024). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions">Source</a></p><p>[4] Snowflake. Understanding overall cost. <a href="https://docs.snowflake.com/en/user-guide/cost-understanding-overall">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c9cac02000c0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Postmarket MedTech Evidence Needs a Question Before a Dashboard]]></title>
            <link>https://medium.com/@yadav_ashish/postmarket-medtech-evidence-needs-a-question-before-a-dashboard-8490a466ba58?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/8490a466ba58</guid>
            <category><![CDATA[medtech]]></category>
            <category><![CDATA[post-market-surveillance]]></category>
            <category><![CDATA[data-governance]]></category>
            <category><![CDATA[medical-devices]]></category>
            <category><![CDATA[clinical-evidence]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Mon, 02 Nov 2026 14:56:01 GMT</pubDate>
            <atom:updated>2026-11-02T14:56:01.750Z</atom:updated>
            <content:encoded><![CDATA[<p>Postmarket evidence has to begin with the question a medical device company needs to answer. Is a malfunction becoming more frequent? Does a training change improve use? Are outcomes different after expansion to new care settings? Each question needs a different combination of event definition, exposure, follow-up, and clinical context.</p><p>Combining complaints, service records, registries, sales, and field feedback can improve visibility. It can also make unlike observations appear comparable. Units shipped do not establish procedures performed; a complaint count does not establish an incidence rate; and an observed improvement after a product change does not establish that the change caused it.</p><p>My background across devices, diagnostics, quality, and clinical development has shaped how I assess these data. A signal should lead to a defined investigation and a proportionate decision. The company needs to know what it observed, which alternative explanations remain, and what evidence would justify action.</p><p>The examples below are illustrative. They describe an approach to combining postmarket sources while preserving the limitations that matter to safety, effectiveness, and product claims.</p><h3>Decide what an event represents</h3><p>Suppose a team sees an increase in reported device malfunctions. The first question is whether malfunctions have increased or reporting has changed. A new distributor may be better at documenting complaints. A training campaign may encourage clinicians to report issues previously handled locally. An installed base may have expanded. A product update may have changed how an error is logged.</p><p>None of these explanations should be presumed. The team should define the event, source, reporting pathway, and denominator before interpreting a trend. A complaint count is an important signal but not necessarily an incidence rate. A service ticket can reflect a hardware failure, user error, software configuration, or routine maintenance. The categories need enough precision to support investigation.</p><p>The record should include product model, version, lot or serial number when relevant, geography, care setting, procedure type, user training status, and date of use. These details may help distinguish a product problem from a workflow or reporting change. They also allow a targeted response rather than a broad assertion that all devices perform the same way.</p><p>The team should preserve the original report and subsequent coding decisions. If a complaint is reclassified after investigation, both states matter. The audit trail allows reviewers to see whether an apparent trend changed because the underlying events changed or because the coding rule did.</p><p>Boston Scientific’s public cardiac rhythm management Product Performance Resource Center distinguishes product survival information, confirmed malfunction details, and advisories. That distinction is instructive: different evidence types answer different questions. A manufacturer’s product performance report is not interchangeable with a registry outcome analysis or a raw complaint count. Reviewers need to understand how events were confirmed and how exposure or follow-up was estimated before drawing a conclusion from any of them. [4]</p><h3>Use denominators that match the question</h3><p>Reports per unit sold can be a convenient measure, but sales are not the same as use. Devices may remain in inventory, be used at different frequencies, or support different numbers of patients. An implant may require follow-up time; a reusable instrument may have many procedures; software may reach users through subscriptions whose active use varies.</p><p>For a procedural device, procedures performed may be a more relevant exposure than units shipped. For an implant, patient-years or time since implantation might matter. For software, active eligible encounters may be informative. Each denominator has its own data quality problems. The team should state what it measured and what it could not measure.</p><p>Comparing sites requires care. A high-volume center may have more events in absolute terms but a lower event rate. It may also treat more complex patients, use a newer technique, or report more consistently. A raw ranking can unfairly label it as poor performing or hide an issue elsewhere.</p><p>Show trends with uncertainty and investigate changes in ascertainment. A small site can swing dramatically after one event. An apparently stable aggregate can conceal a signal tied to one version or training pathway. A dashboard should let qualified reviewers move from the overall pattern to the underlying records without presenting every fluctuation as proof.</p><h3>Link clinical outcomes to the right context</h3><p>Postmarket evidence may include registry outcomes, chart reviews, claims, and prospective studies. Each answers a different question. A registry can provide richer clinical detail but may cover selected centers. Claims may have broad reach but limited clinical specificity. A targeted study can define endpoints carefully but may be smaller or slower.</p><p>Specify an estimand or plain-language outcome question before combining sources. What population and intervention are being evaluated? At what time after use? Which outcome matters? What happens when a patient receives additional treatment or is lost to follow-up? Without these choices, the team may compare rates that describe different clinical situations.</p><p>Patient selection matters. Early adopters may be expert centers using careful eligibility criteria. Expansion to more settings can change outcomes even if the device itself is unchanged. A worse crude rate does not necessarily mean the product deteriorated; it could reflect a broader or sicker population. Conversely, attributing every concerning signal to case mix can delay a necessary investigation.</p><p>The team should distinguish a descriptive safety signal from evidence of causal benefit or harm. Observational comparisons are vulnerable to confounding. They can guide questions and surveillance, but a promotional claim about superiority may require a different evidence package. The strength of the conclusion should match the design and data.</p><h3>Make product changes visible</h3><p>Medical devices evolve. Software, components, packaging, sterilization, manufacturing sites, instructions, and training may change. A postmarket dataset that treats all versions as one exposure can conceal both improvement and a new problem.</p><p>Maintain a timeline of product and process changes linked to deployments and reports. A signal appearing after an update deserves investigation, but temporal proximity alone does not establish cause. The team should examine which devices actually received the update, where they were used, and whether reporting or use changed at the same time.</p><p>The same applies to training. A new clinical technique or revised instructions can alter outcomes. If adoption metrics improve after a training program, the organization needs to know who received it and whether other factors changed. A dashboard with only calendar month and product name will not answer that question.</p><p>Version-aware analysis also supports communication. If an issue affects a defined configuration, clinicians and customers need clear guidance about the affected population and recommended action. An inability to identify exposed units can turn a targeted response into a wider, more disruptive one.</p><h3>Complaints and clinical evidence must talk to each other</h3><p>Quality systems may handle complaints through established investigation and reporting procedures. Clinical affairs may analyze outcomes in a registry. Commercial teams may hear user concerns through field staff. If these streams remain separate, an organization can miss a pattern that none of them reveals alone.</p><p>Establish a controlled cross-functional review for signals that might affect safety, effectiveness, usability, or claims. Quality retains responsibility for the required complaint and corrective-action processes. Clinical specialists assess outcome patterns and context. Regulatory colleagues determine applicable reporting and change implications. Data teams trace sources and versions. Field teams can clarify how the product is used, while respecting boundaries on interpretation and communication.</p><p>The review should state a hypothesis and a plan to test it. Suppose reports of a complication rise at sites with recent staff turnover. Is training the cause, a proxy for another workflow change, or merely more visible reporting? The next step might be a structured chart review, site visit, or targeted education, followed by a defined check. It should not be an unsupported conclusion in a management presentation.</p><p>Keep a decision record of what was known, which alternatives were considered, and why the team acted. That record is useful whether the signal leads to a correction, further evidence gathering, or no immediate change. It also prevents later reviewers from judging an earlier decision using facts that were unavailable then.</p><p>In the United States, FDA’s QMSR became effective on February 2, 2026 and incorporates ISO 13485:2016 by reference. Applicable complaint and reporting duties should be handled through the manufacturer’s established quality and regulatory processes. Cross-functional analysis supplements those processes; it does not replace Medical Device Reporting obligations. [2, 3]</p><h3>The reporting system is part of the evidence</h3><p>Postmarket data are produced by people and systems with incentives, burdens, and limitations. A difficult complaint form may lead to incomplete descriptions. A service system may prioritize restoring functionality over capturing clinical context. A field team may receive feedback but not know which formal route it belongs in.</p><p>Examine the reporting process itself. Are users aware of how to report an event? Can the company follow up for relevant details? Are similar cases coded consistently? Do multiple systems create duplicate reports? Are there delays from event to receipt and from receipt to assessment? These measures help interpret the apparent trend.</p><p>Data quality improvement can produce a short-term rise in events. That may be good news for surveillance even if the chart looks worse. Leadership should be prepared to explain why better detection and a worsening product signal are different possibilities requiring different actions.</p><p>The organization should also monitor whether the absence of reports is credible. A region with substantial use and almost no complaints could have excellent performance or a weak reporting channel. The data alone cannot decide. A targeted process review may be more informative than another statistical threshold.</p><h3>Use public adverse event data carefully</h3><p>FDA’s MAUDE database contains medical device adverse event reports. It can help generate safety questions and identify reported patterns. FDA warns that the database has limitations and cannot be used by itself to determine event rates or compare devices. Reports may be incomplete, duplicated, or affected by reporting practices. [1]</p><p>Public reports should inform a structured investigation. They are unsuitable as a leaderboard of competing products. A product with more reports may have a larger installed base or more active reporting. A dramatic narrative in one report may deserve attention while still requiring verification and clinical context.</p><p>Public data can support regulatory intelligence and signal detection when handled responsibly. The team should document search terms, date range, inclusion decisions, and limitations. It should avoid implying that the absence of a reported event proves safety. Further assessment may require the manufacturer’s controlled records, clinical evidence, and expert review.</p><p>The same discipline applies to publicly discussed recalls and safety communications. They describe actions in specific contexts. A company should not use an unrelated event to infer that its own product is safer without an appropriate comparison.</p><h3>Measure the response not just the signal</h3><p>Once a concern is detected, the effectiveness of the response becomes another evidence question. Did the organization identify affected devices and users? Did the communication reach them? Did training change technique? Did a design correction reduce the relevant failure mode? What unintended burdens did the response create?</p><p>Set a follow-up window and measure the mechanism the action was supposed to improve. If the intervention was a revised instruction, simply counting distributed copies is weak evidence. The team might assess comprehension, correct use in observation, and subsequent event patterns, while accounting for changes in reporting.</p><p>Some signals will remain uncertain. The decision may be to intensify surveillance or conduct a study. The important point is to state the uncertainty, proportional action, and trigger for escalation. A green dashboard status should not conceal an unresolved question with material consequences.</p><p>Leadership should receive a concise narrative: what was observed, who or what may be affected, what alternative explanations were tested, what action was taken, and what evidence will show whether it worked. This is more useful than a dense page of uncontextualized rates.</p><h3>A practical first ninety days</h3><p>Select one product family and one or two consequential questions. Map the complaint, service, clinical, and exposure sources. Define terms, versions, denominators, and data owners. Review a sample of records manually to test whether the proposed categories represent what happened. Only then build a dashboard.</p><p>The initial dashboard should display data completeness and latency alongside event trends. It should preserve the ability to drill into controlled records for authorized investigation. The team should test a hypothetical event: can it identify the affected configuration, exposure estimate, relevant clinical context, reporting status, and decision owner?</p><p>In the second month, review signals across quality, clinical, regulatory, and data functions. Document decisions and unresolved questions. In the third, test whether an action changed the expected process and whether the data sources need improvement. The dashboard should be modified when the review reveals a misleading measure.</p><p>This approach does not promise a perfect view of real-world performance. It creates a credible way to learn. Postmarket evidence is strongest when the organization can explain where a signal came from, what it might mean, and why its response is proportionate to the available facts.</p><h3>The larger point</h3><p>Medical device performance is experienced in clinical practice, not only in a premarket study. Postmarket learning can improve design, training, patient selection, and evidence generation. It can also be distorted by incomplete exposure, inconsistent reporting, and changing use.</p><p>The surveillance program should be assessed by whether its findings lead to well-supported action. That includes the ability to investigate alternative explanations, identify affected devices or users, and test whether a correction addressed the relevant failure mode.</p><p>Revisit the questions periodically and after material changes. As a device matures, the most important uncertainty may change from early usability to durability, performance in broader settings, or a new product version. A surveillance dashboard designed for the first year should not become the permanent definition of evidence. The questions should follow the product and the patients who use it.</p><h3>Sources</h3><p>[1] U.S. Food and Drug Administration. <em>About the Manufacturer and User Facility Device Experience (MAUDE) Database.</em> <a href="https://www.fda.gov/medical-devices/mandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities/about-manufacturer-and-user-facility-device-experience-maude-database">Source</a></p><p>[2] U.S. Food and Drug Administration. <em>Quality Management System Regulation (QMSR).</em> <a href="https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr">Source</a></p><p>[3] U.S. Food and Drug Administration. <em>Medical Device Reporting (MDR): How to Report Medical Device Problems.</em> <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">Source</a></p><p>[4] Boston Scientific. Cardiac Rhythm Management Product Performance Resource Center. <a href="https://www.bostonscientific.com/en-US/pprc.html">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8490a466ba58" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Monitoring Clinical AI Across Hospitals Is a Systems Problem]]></title>
            <link>https://medium.com/@yadav_ashish/monitoring-clinical-ai-across-hospitals-is-a-systems-problem-f39672bc16d3?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/f39672bc16d3</guid>
            <category><![CDATA[clinical-ai]]></category>
            <category><![CDATA[healthtech]]></category>
            <category><![CDATA[ai-validation]]></category>
            <category><![CDATA[patient-safety]]></category>
            <category><![CDATA[digital-health]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Fri, 30 Oct 2026 15:51:01 GMT</pubDate>
            <atom:updated>2026-10-30T15:51:01.315Z</atom:updated>
            <content:encoded><![CDATA[<p>Deploying a clinical AI tool at a second hospital introduces a new operating environment, even when the model is unchanged. Laboratory interfaces, documentation, devices, staffing, and escalation routes may differ. The resulting performance problem can appear to be model drift when its cause is a change elsewhere in the clinical pathway.</p><p>Consider a hypothetical deterioration alert that performs well during evaluation but reaches the receiving team after it has already made the relevant care decision. Improving the model’s discrimination will not repair the timing. The monitoring record needs to show when the data arrived, when the output was generated, who received it, and whether an appropriate response was possible.</p><p>My perspective comes from life sciences, medical technology, and regulated product decisions. The question I bring to monitoring is operational: which finding will cause which person to investigate, change, limit, or pause the system? Metrics are useful only when their interpretation and response are defined.</p><p>Across hospitals, the unit being monitored should include the model and its implementation. A versioned account of the data pipeline, local configuration, user workflow, and outcome definition gives the team a basis for understanding what changed.</p><h3>Define the unit of deployment</h3><p>Suppose an AI tool estimates the risk of deterioration for hospitalized patients. It receives vital signs and laboratory results, calculates a score, and places an alert in the clinical workflow. A vendor may regard the deployed unit as a model version. A hospital experiences a larger unit: data feed, feature mapping, threshold, alert routing, staffing pattern, and escalation protocol.</p><p>Each hospital may implement that unit differently. A laboratory test with the same name might use a different analyzer or unit. A ward may record observations on a different schedule. A nighttime alert may reach a nurse covering more patients than the daytime recipient. Monitoring only discrimination on a pooled sample can miss these local conditions.</p><p>Maintain a deployment manifest for every site: intended use, eligible population, exclusions, source systems, variable definitions, model and preprocessing versions, decision threshold, alert recipient, response protocol, and dates of relevant changes. This is ordinary configuration management applied to a clinical decision pathway. Without it, investigators cannot tell whether a performance change reflects the model, the data, or implementation.</p><p>The manifest should be versioned and linked to actual predictions. If a patient safety concern emerges, the team needs to identify which patients saw which system configuration. A current screenshot of settings is insufficient. The audit trail must preserve the state at the time of use.</p><p>Digital pathology is another relevant setting. Roche’s public PathAI announcement connects AI analysis with laboratory workflows and companion diagnostics. For an image-analysis application deployed across laboratories, the monitoring record should identify the scanner, preparation process, software version, and intended use. A local change can affect the conditions under which an output is interpreted even when the model’s central version remains fixed. That configuration history gives the investigator a starting point for examining a performance concern. [4]</p><h3>Monitor data before outcomes arrive</h3><p>Clinical outcomes may take time to mature or be difficult to define consistently. Input data can often be checked sooner. Input monitoring should cover missingness, unexpected values, units, timestamps, source-system changes, and the proportion of patients excluded from scoring. A stable average score can conceal a rising number of patients who never receive a score because one field is missing.</p><p>Data quality measures need local interpretation. A sudden increase in missing laboratory values might reflect an interface failure, a change in ordering practice, or a difference in patient acuity. An automated alert should open an investigation, not announce a cause. The team should include people who understand the source systems and clinical workflow.</p><p>Population mix deserves similar attention. Age, disease severity, care setting, and relevant comorbidities may shift. Some differences are expected and do not automatically imply poor model performance. They tell the team where to seek outcome evidence and whether the deployed population still matches the intended use.</p><p>Monitoring should avoid creating a false sense of certainty from small local samples. A hospital with few events may show a dramatic month-to-month change in a metric by chance. Pooling can improve precision, but it can also hide a problem concentrated at one site. Report site-level estimates with uncertainty and examine clinically meaningful subgroups when sample size and data quality permit.</p><h3>Define the outcome carefully</h3><p>For a deterioration tool, the outcome might be ICU transfer, emergency intervention, mortality, or a composite. Each can be influenced by the alert itself and by local care practices. A successful intervention may prevent an event, making an accurate early warning appear to be a false positive under a naive retrospective analysis. A hospital that changes its transfer policy can alter the measured outcome without changing patient risk.</p><p>Distinguish model performance from pathway performance. The former asks whether predictions correspond to an appropriately defined clinical outcome. The latter asks whether alerts reach the right people, prompt appropriate actions, and improve care without excessive burden. Both matter. Neither can be inferred from click-through rates alone.</p><p>Feedback labels need governance. When an outcome is derived from billing codes or chart review, its definition, delay, and error rate should be recorded. If outcome ascertainment changes between sites, a cross-site comparison may be misleading. A model can appear better where documentation is more complete.</p><p>Prospective evaluation may be needed for high-impact claims. Observational monitoring can identify signals and support operational control, but it cannot always establish that the AI caused an improvement. The appropriate evaluation depends on intended use, risk, and the decisions being made.</p><h3>Separate four kinds of change</h3><p>Classify an observed change before selecting a remedy. First is input change: the values, missingness, or measurement process differ. Second is relationship change: the same inputs relate differently to the outcome. Third is workflow change: a prediction reaches people differently or prompts a different action. Fourth is outcome-definition change: the event used to judge performance is recorded differently.</p><p>The categories overlap, but they prevent premature retraining. If a laboratory unit was mapped incorrectly, collecting more local data and retraining a model could embed the error. If alerts arrive after morning rounds, changing a score threshold may increase noise without solving timing. If the case mix shifts, a calibration update may be appropriate in some circumstances, but only after the population and intended use are examined.</p><p>Every proposed intervention should have a hypothesis and validation plan. A corrected data mapping needs replay or comparison on affected records. A threshold change needs an estimate of alert volume, missed cases, and clinical burden. A model update needs version control, validation in the relevant settings, and a plan for monitoring after release.</p><p>This is a quality improvement loop with technical evidence. The team should be able to explain what was observed, what it believes caused the issue, what it changed, and how it checked the result.</p><h3>Set thresholds that trigger action</h3><p>A monitoring threshold should be tied to a response. Some failures justify an immediate pause: a corrupted input feed, predictions for excluded patients, or a serious safety signal. Other signals call for review, such as a gradual increase in missing data or a widening calibration gap. A minor change within expected variability may simply be watched.</p><p>Define three escalating levels of response: automated integrity check and technical triage; multidisciplinary review of performance and workflow; and formal change control or suspension. The exact levels depend on the product and setting. The point is to remove ambiguity when a signal appears at an inconvenient time.</p><p>Ownership must cross organizations. The vendor may control the model. The hospital may control its electronic record, clinical protocol, and response team. An integration partner may control a feed. The contract and operating procedure should say who can pause the tool, who investigates, who informs clinicians, and who maintains the record of affected decisions.</p><p>FDA’s device guidance on predetermined change control plans and its lifecycle work for AI-enabled devices illustrate why changes must be planned and evaluated in context. A specific product’s regulatory obligations depend on its classification and intended use. Monitoring design should be built with the applicable quality and regulatory team rather than copied from a generic software playbook. [1, 2]</p><h3>Alert burden is a safety metric</h3><p>An AI system can preserve statistical performance while producing too many alerts for a clinical team to act on. Staffing, patient volume, and competing notifications vary by hospital and shift. Monitor alerts per clinician, acknowledgment and response times, overrides, and the reasons for nonresponse, while recognizing that a click is not the same as a beneficial action.</p><p>The cost of a false alert is more than a few seconds. It may interrupt care, drive unnecessary testing, or reduce attention to future warnings. The cost of a missed alert can be serious. Threshold selection should therefore reflect clinical capacity and consequences, not a single pooled metric optimized before deployment.</p><p>Qualitative feedback is essential. Clinicians can explain that alerts arrive after a decision was already made, repeat information they know, or omit context needed for action. A monitoring system that never asks users about those conditions will misdiagnose workflow failure as model failure or success.</p><p>Also examine whether alerts work differently across patient groups and care settings. A tool used where staffing is thin may have less benefit even with identical model performance. Equity analysis should therefore include access to the intervention triggered by the prediction, not merely parity in scores.</p><h3>Make a monitoring record that can be audited</h3><p>A useful record links each prediction to source data timestamps, transformations, model version, threshold, delivery status, recipient, and subsequent action where available. It should respect privacy and security requirements while allowing authorized investigation. The organization needs enough detail to reconstruct a reported event and evaluate whether others were affected.</p><p>Aggregate dashboards remain useful, but they should sit on this traceable foundation. The review should include site-level data health, coverage of the intended population, calibration and error measures with uncertainty, alert burden, workflow response, safety events, and open investigations. A single green status obscures too much.</p><p>The review cadence should reflect clinical risk and data latency. A broken interface may need same-day detection. Outcome analysis may be monthly or quarterly. Formal periodic review should examine accumulated evidence, model and system changes, and whether the intended use remains appropriate.</p><p>NIST’s AI Risk Management Framework provides a general structure for mapping, measuring, and managing AI risk. It is useful as a common language across the vendor and health system. It does not specify a clinical monitoring plan for a particular product. That plan must be constructed from the intended use and the consequences of failure. [3]</p><h3>A practical first deployment</h3><p>Before the first hospital goes live, run the complete pipeline in shadow mode and compare source values with model inputs. Test missing data, unexpected values, duplicates, time-zone changes, and downtime. Confirm when the recommendation would appear and whether the intended recipient can act on it. Shadow evaluation can assess the technical pathway; it does not establish the benefit of clinicians acting on an alert.</p><p>During initial live use, review a sample of cases closely, including alerts and nonalerts. The goal is to see whether the technical record matches what clinicians experienced. Document early overrides and support requests. Those observations can reveal problems that a large aggregate performance estimate cannot.</p><p>Before adding a second hospital, distinguish what must remain constant from what may be configured locally. Local thresholds or workflows may be legitimate, but each configuration becomes a distinct deployment to monitor. A single performance number across sites is inadequate when their use cases or response pathways materially differ.</p><p>The same principle applies when the tool expands to new wards, languages, or patient groups. Expansion is a new evidence question, not merely a procurement event. A monitoring program should make those boundaries visible.</p><h3>The purpose of monitoring</h3><p>Monitoring is sometimes portrayed as a promise that a model will stay accurate forever. That is not realistic. Its purpose is to detect meaningful changes, investigate them with enough context, and make timely decisions about continued use, correction, or withdrawal.</p><p>An investigation should identify the affected setting and population, the configuration in use, the change that preceded the signal, and the action taken. Those details allow the hospital and provider to address an actual failure mechanism instead of treating every decline as a request to retrain the model.</p><p>Clinical AI operates in changing organizations. Treating the model as one component of a governed clinical pathway is how we keep its performance claims connected to actual care.</p><h3>What to report to leadership</h3><p>Start the leadership review with the number of eligible people, the number actually scored, and reasons for exclusion. Then present clinical outcomes and alert measures by deployment, with confidence intervals or another appropriate account of uncertainty. Incidents and unresolved investigations belong in the same review as favorable metrics. A product can have an attractive average score and an unacceptable local failure.</p><p>The review should end in decisions: continue, modify, collect more evidence, limit the intended population, or pause. Each decision needs an owner and date for reassessment. If a team repeatedly sees the same warning without action, the dashboard has become a ritual. Monitoring earns its place when it changes what the organization does.</p><p>One useful challenge is to ask the hospital and vendor to walk through a hypothetical adverse event together. Can they retrieve the exact input and output, identify the responsible configuration, see whether the alert was delivered, and explain the response? If that exercise takes weeks or relies on memory, the monitoring design needs improvement before wider deployment.</p><h3>Sources</h3><p>[1] U.S. Food and Drug Administration. <em>Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations</em> (draft guidance, 2025). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing">Source</a></p><p>[2] U.S. Food and Drug Administration. <em>Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions</em> (final guidance, 2025). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence">Source</a></p><p>[3] National Institute of Standards and Technology. <em>AI Risk Management Framework.</em> <a href="https://www.nist.gov/itl/ai-risk-management-framework">Source</a></p><p>[4] Roche. Definitive merger agreement to acquire PathAI (May 7, 2026). <a href="https://www.roche.com/media/releases/med-cor-2026-05-07">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f39672bc16d3" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Interoperability Is a Clinical Meaning Problem]]></title>
            <link>https://medium.com/@yadav_ashish/interoperability-is-a-clinical-meaning-problem-9c548cb2abaf?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/9c548cb2abaf</guid>
            <category><![CDATA[health-data]]></category>
            <category><![CDATA[data-engineering]]></category>
            <category><![CDATA[interoperability]]></category>
            <category><![CDATA[fhir]]></category>
            <category><![CDATA[clinical-research]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Tue, 27 Oct 2026 21:46:01 GMT</pubDate>
            <atom:updated>2026-10-27T21:46:01.687Z</atom:updated>
            <content:encoded><![CDATA[<p>A laboratory result can reach a receiving system with a valid code, value, unit, and timestamp while leaving the most consequential question unanswered: is it appropriate for the decision being made now?</p><p>For a biomarker result, the answer may depend on the specimen, assay method, cutoff, report status, and treatment history. Those details do not become interchangeable because the record has been represented in a standard format. A receiving application has to preserve enough context to distinguish results it can use from results that require further review.</p><p>My work across diagnostics, clinical development, and medical technology has made this distinction important to me. Information often travels beyond the team that generated it. At the receiving end, a familiar field name can create confidence that the underlying evidence does not support.</p><p>Health data interoperability should be judged by whether the information remains interpretable for its intended use. Standards and APIs make exchange possible. Clinical and laboratory expertise determine which mappings preserve meaning, where uncertainty remains, and when a receiving system should decline to act.</p><h3>Exchange is necessary but not sufficient</h3><p>FHIR, developed by HL7, provides a framework for exchanging healthcare information electronically. Its resources, references, profiles, and terminology mechanisms make many forms of data exchange more practical. USCDI defines a common set of data elements for interoperable exchange in the United States. CDISC standards organize clinical research data for collection, analysis, and submission. [1, 4]</p><p>These are major accomplishments. They solve parts of a difficult problem. A FHIR Observation can carry a laboratory value in a recognizable structure. It does not guarantee that every sending organization measures the same clinical concept in the same way, uses the same assay, or records the event at the same point in care.</p><p>The gap is visible when an application moves from displaying data to making recommendations. A clinician reading a report may recognize that a value is from an old specimen and should not guide today’s decision. A model receiving a normalized field may not know the same thing unless the context is preserved in its inputs and rules.</p><p>Interoperability therefore has at least three layers. Technical exchange asks whether systems can communicate. Semantic exchange asks whether fields and codes carry a shared definition. Decision interoperability asks whether the receiving organization can use the information responsibly for the intended task. Progress in one layer does not automatically complete the others.</p><p>Microsoft’s FHIR service in Azure Health Data Services provides managed storage and exchange through FHIR APIs, with role-based access and audit logging. Those capabilities help operate an interface. They do not determine whether two biomarker results represent equivalent clinical evidence. A buyer still needs to specify the method, specimen, timing, and report context required by its application, then test whether the source and mapping preserve them. This is a clinical acceptance question within a technical implementation. [5]</p><h3>A coded result can still be ambiguous</h3><p>Suppose a system receives a biomarker result marked “positive.” Positive according to which assay, threshold, specimen, and clinical use? A different cutoff could change the classification. A tumor sample taken before several therapies may not represent the present disease in the same way as a recent specimen. A result generated for research may not be interchangeable with a validated clinical test.</p><p>The code and status are important. So are method, specimen, date, laboratory, report version, and any interpretive comments. Some of these may be available as structured elements. Others may be embedded in a document or absent from the exchanged record.</p><p>The receiving organization should know which information is required for its decision. A dashboard counting how many patients had a test may need less detail than a trial matching tool deciding whether a result meets a protocol criterion. A treatment-selection application may need still more assurance about assay and intended use.</p><p>The engineering team cannot resolve this alone by mapping all variants of “positive” into one normalized value. Clinical and laboratory experts need to define when results are equivalent and when the application should abstain or request review.</p><p>Terminology mapping therefore requires clinical judgment. A mapping table should record the source concept, target concept, scope, assumptions, and known exceptions. It should be tested with records that sit at the boundary, not only easy examples.</p><h3>Time is often the missing dimension</h3><p>Health data carry several dates: when an event occurred, when it was documented, when a result was finalized, when it was corrected, and when another system received it. These dates answer different questions.</p><p>For a clinical trial, a model may need to know what was available before consent or randomization. A final EHR record may include information entered after that point. Using the latest version in a retrospective model can create leakage. The system appears to make an early prediction because it has been given a later fact.</p><p>For a safety workflow, a delay between event and report can matter. For a diagnostic interpretation, a specimen collection date can matter more than the date the report was viewed. A generic “observation date” may be insufficient if the application is expected to act on the result.</p><p>Data pipelines should preserve relevant timestamps rather than overwrite them with ingestion time. They should also retain corrections and version history where the decision requires reconstruction. A receiving user may need to know whether a value was provisional at the time it influenced a decision.</p><p>This is not merely a technical detail. Time determines whether evidence was available, whether it was current, and whether a later correction should change an earlier analysis.</p><h3>FHIR to research mapping requires judgment</h3><p>Clinical care data and clinical research data are created for different purposes. An EHR records care. A trial protocol defines specific observations, timing, and quality expectations to answer a research question. Mapping between them can reduce duplicate entry and improve efficiency, but it does not make every EHR value suitable for a study.</p><p>CDISC and HL7 have published a version-specific FHIR-to-CDISC mapping implementation guide to facilitate the flow of EHR information into research standards. Version 1.0 maps FHIR R4 to specified versions of CDASH, SDTM, and laboratory standards. Implementers should verify the versions supported by their actual systems. The mapping is an important bridge. The receiving study still needs to assess whether a value matches the protocol definition, visit window, specimen requirement, and source-data expectations. [2]</p><p>Imagine an EHR laboratory result that could populate a trial case report form. Was the test performed at an acceptable laboratory? Was it collected within the required window? Is the unit convertible without changing interpretation? Did the result include a flag or comment that the trial system cannot represent? Was it corrected later?</p><p>If the workflow answers these questions explicitly, it may save site effort and improve traceability. If it merely imports a value because a code matches, it can move an ambiguity into a more formal-looking dataset.</p><p>FDA’s guidance on use of EHR data in clinical investigations addresses considerations for sponsors, investigators, CROs, and others. The general lesson is that an exchanged record must remain reliable and verifiable for the research use. An interface does not remove the sponsor’s need to understand its data. [3]</p><h3>Context should travel with the value</h3><p>The ideal exchanged record does not need to carry every possible detail for every possible future use. That would be impractical. It should carry the context necessary for its defined uses and allow the receiving system to obtain more when the decision requires it.</p><p>A data product should answer four questions. What is the value? How was it generated? When was it known? What limitations affect its use? For a critical field, these questions should have answers that can be inspected rather than inferred from naming conventions.</p><p>Some context can be encoded in structured metadata. Other context may require a linked report, provenance record, or documented transformation. The design should make uncertainty visible. A missing assay version should not silently become “standard assay.” A result from an unknown specimen should not be treated as equivalent to a confirmed tissue type merely because both can be represented in the same resource.</p><p>The consumer of the data should specify the minimum context it needs. That requirement can then be tested against the sources. If a source cannot supply it, the application may need to restrict use, request human review, or gather additional information.</p><p>This approach also makes procurement more precise. A buyer can ask a vendor to demonstrate how its system handles a corrected laboratory report, an ambiguous code, or a result tied to an older specimen. The answer reveals more than a general claim of FHIR compatibility. It shows whether the product preserves the context needed for the buyer’s actual decisions and whether exceptions can be resolved without hidden manual work.</p><p>The specification should state both the supported uses and the information gaps that require further review.</p><h3>Identity and linkage can fail quietly</h3><p>Clinical information may be spread across health systems, laboratories, trial sites, and vendors. Linking records to the right person, specimen, study, and event is foundational. Errors can be difficult to detect because the linked data may look plausible.</p><p>An oncology patient can have multiple biopsies, lesions, lines of therapy, and laboratory results. If a biomarker result is linked to the wrong specimen or treatment period, the resulting analysis may be clinically misleading even when each individual record is accurate.</p><p>The data architecture should preserve relationships among patient, encounter, order, specimen, observation, report, and study event where needed. Reconciliation rules should be explicit, and uncertain matches should be flagged. A system should not turn a probabilistic linkage into a confirmed clinical fact without an appropriate review.</p><p>Privacy and access must also be built into the linkage approach. More complete longitudinal data can improve research, but the ability to join records across settings creates responsibilities for consent, authorization, security, and appropriate use.</p><p>An AI application should receive only the information it needs for its defined task and should have a clear route to source review when the result is questioned.</p><h3>Quality must be measured by use</h3><p>Technical quality checks can confirm that a feed is available, schemas are valid, codes come from allowed sets, and required fields are populated. Semantic checks ask whether the values make sense in context. Decision-specific checks ask whether any remaining uncertainty is acceptable for the use.</p><p>For a population health dashboard, a delayed noncritical observation may be tolerable. For trial eligibility, a missing date or assay method may require manual confirmation. For an automated alert, the same uncertainty could make the system unsuitable for action.</p><p>Quality reporting should show coverage as well as accuracy. A system that produces excellent predictions for 60% of patients with complete records may have a larger practical limitation than a system with a slightly lower metric but broader reliable coverage. Examine who is excluded and whether missingness varies by site, geography, care setting, or patient group.</p><p>Domain experts should participate in quality-rule design. A generic outlier rule may flag a clinically valid extreme value. A record that passes numeric bounds may still be implausible because it conflicts with treatment timing or specimen type.</p><p>Quality checks need owners and responses. A flag that no one investigates becomes background noise.</p><h3>The interface should expose uncertainty</h3><p>Interoperability is often assessed by the people building the connection. It should also be assessed by the person using the information. Can a clinician see the original report when a result matters? Can a trial coordinator distinguish a confirmed eligibility criterion from a possible match? Can an analyst identify which source, version, and transformation produced a field? Can a data steward resolve a mapping exception without rewriting the entire pipeline?</p><p>An application that suppresses uncertainty may feel easier to use while creating a false sense of precision. A well-designed interface can show a concise status: confirmed, derived under a specified rule, provisional, conflicting, or unavailable. The display should support action without burying the user in metadata.</p><p>The system should allow a qualified person to correct a linkage, challenge an interpretation, and document why. That feedback should improve the source process or mapping, not disappear into an individual note.</p><h3>A practical test before calling data interoperable</h3><p>Choose a small set of difficult cases and ask clinical, laboratory, research, and engineering colleagues to reconstruct the same answer. Include corrected results, multiple specimens, unit conversions, ambiguous codes, incomplete dates, and records spanning different care settings.</p><p>Then ask whether the receiving system can support the intended decision. If the team reaches different interpretations, document the source of disagreement. Is the information absent, represented differently, mapped too broadly, or understood differently by the functions? Fix the contract or limit the use before scaling.</p><p>The test should be repeated after material changes to source systems, terminology, assays, or workflows. Interoperability is not a one-time certification that settles every downstream use. Teams should keep the difficult cases as a regression set. When a source system changes or a new laboratory joins, rerun them and add new failures. This creates a practical memory of why mappings were designed as they were. It also makes a future migration safer: the organization can test whether the new connection preserves the interpretations on which existing reports and models depend.</p><p>Standards make it possible to exchange information at scale. Their value increases when implementers are explicit about clinical meaning and provenance. The goal is not to ask every API to solve medicine. It is to prevent an application from treating a transported value as more certain or more comparable than it is.</p><p>The receiving team should be able to explain why the information supports its intended use. That is the standard against which an interface, mapping, and analytical application should be assessed. When the context is insufficient, a visible exception is preferable to a standardized value that quietly invites the wrong interpretation.</p><h3>Sources</h3><p>[1] HL7 International. <em>FHIR Overview</em> and <em>Terminology Module.</em> <a href="https://hl7.org/fhir/">Source</a></p><p>[2] CDISC. <em>Real World Data and FHIR-to-CDISC Joint Mapping Implementation Guide.</em> <a href="https://www.cdisc.org/standards/real-world-data">Source</a></p><p>[3] U.S. Food and Drug Administration. <em>Use of Electronic Health Record Data in Clinical Investigations</em> (2018). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry">Source</a></p><p>[4] ASTP/ONC. <em>Standards Version Advancement Process — Approved Standards for 2025.</em> <a href="https://healthit.gov/resources/standards-version-advancement-process-approved-standards-for-2025/">Source</a></p><p>[5] Microsoft. What is the FHIR service in Azure Health Data Services? <a href="https://learn.microsoft.com/en-us/azure/healthcare-apis/fhir/overview">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9c548cb2abaf" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A Practical Architecture for AI Assisted Medical Legal and Regulatory Review]]></title>
            <link>https://medium.com/@yadav_ashish/a-practical-architecture-for-ai-assisted-medical-legal-and-regulatory-review-a8905950e6c5?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/a8905950e6c5</guid>
            <category><![CDATA[medical-affairs]]></category>
            <category><![CDATA[generative-ai]]></category>
            <category><![CDATA[regulatory-affairs]]></category>
            <category><![CDATA[ai-governance]]></category>
            <category><![CDATA[life-sciences]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Fri, 23 Oct 2026 00:41:01 GMT</pubDate>
            <atom:updated>2026-10-23T00:41:01.804Z</atom:updated>
            <content:encoded><![CDATA[<p>Medical, legal, and regulatory review depends on the relationship between a claim and its evidence. A sentence may be accurate in isolation yet misleading in a headline, unsupported for the intended population, or inconsistent with the product information applicable in a particular market. Faster text generation does not resolve those judgments.</p><p>Generative AI can help reviewers locate sources, identify claims, compare versions, and assemble questions for specialist review. An agentic design can coordinate those tasks. The architecture has to preserve what the system examined and where its conclusion came from, otherwise a fluent review summary creates more verification work for the people responsible for approval.</p><p>My experience across regulatory strategy and regulated product development informs the standard I apply here: a qualified reviewer should be able to inspect the original claim, check the relevant evidence, and record an independent decision. That standard shapes the source library, permissions, evaluation, and interface before it shapes the choice of model.</p><p>AWS published an MLR orchestration example using specialized AI agents in June 2026. It is a useful technical reference, not independent evidence that a particular implementation meets a company’s review requirements. The design recommendations below describe how I would assess such an application for a defined product, jurisdiction, and content category. [1]</p><h3>Define the review unit</h3><p>Before selecting a model, define what enters the process. Is it a promotional piece, a medical response, a disease-awareness asset, a field training document, or a proposed claim for a specific channel? Different content has different requirements and approvers.</p><p>The review unit should carry metadata: product, indication, market, audience, channel, asset owner, intended publication date, language, and the version of the content. If that information is absent, the AI system cannot reliably choose the applicable label, references, and policies. It may search a general corpus and return apparently relevant material that does not govern the proposed use.</p><p>The content itself should be represented in a way that preserves context. A claim in a headline can have a different implication from the same words in a balanced paragraph. A citation supporting one part of a sentence may not support the overall takeaway. Images, charts, footnotes, and adjacent safety information can change interpretation.</p><p>An architecture that extracts only text and discards layout may miss a material issue. Multimodal processing can help, but it too needs evaluation against the actual assets the company reviews.</p><h3>Establish an authoritative source layer</h3><p>The knowledge base should distinguish sources by authority and status. Current approved prescribing information, market-specific labeling, core data sheets, approved claims, peer-reviewed publications, congress abstracts, internal policies, and draft documents should not all be treated as equal.</p><p>Each item needs a version, effective date, market, product scope, ownership, and retirement rule. If a label changes, the system should know which version applied to a piece reviewed in the past and which applies to a new asset. A reference library without version control can return an accurate passage from an obsolete document.</p><p>Retrieval should make evidence visible at the passage level. The system should cite the exact portion supporting its observation and provide enough surrounding context for a reviewer to assess it. It should record retrieval failures and uncertainty rather than invent support when the library lacks an answer.</p><p>The source layer also needs a content ingestion process. Who approves a document for use? How is it parsed and checked? What happens when a scanned PDF loses a table or superscript? How are duplicate or conflicting versions detected? The retrieval system’s quality is bounded by those decisions.</p><p>FDA’s Office of Prescription Drug Promotion reviews prescription drug advertising and promotional labeling to assess whether materials are false or misleading. That public role reinforces why a source library cannot be a convenience archive. A claim’s support and its presentation matter. [2, 3]</p><h3>Separate tasks with explicit boundaries</h3><p>An agentic design may include specialized tasks: identify claims, retrieve evidence, compare claims with product information, assess references, check required content, and propose reviewer questions. Specialization is useful when each component has a defined input, output, and limit.</p><p>An unrestricted agent that searches every repository, rewrites the asset, and records approval concentrates incompatible authorities in one component. That system makes it hard to tell where an error originated or whether an action exceeded its authority.</p><p>One component might extract every efficacy, safety, comparative, or mechanism claim and link it to its location in the asset. Another might assess whether a cited source supports the exact claim and note limitations. A third might compare presentation with applicable labeling and policy. The orchestrator can consolidate findings, identify conflicts, and route them to the right reviewer.</p><p>The output should distinguish observation from judgment. “The cited study enrolled a different population” is an observation that can be checked. “The claim is acceptable” is a decision requiring broader context and qualified review. The system should not blur them.</p><p>Agents should be permitted to abstain. If the source is unavailable, the market is unclear, or two references conflict, the correct output may be an unresolved question. A system forced to produce a definitive answer on every pass will be wrong confidently.</p><h3>Permissions should follow the workflow</h3><p>The application will handle sensitive drafts, unpublished data, and potentially confidential partner material. Access should follow product, project, market, and role. A medical reviewer may need different materials from a commercial author. An external agency may be allowed to submit an asset without accessing internal source documents.</p><p>The system should not expose retrieved passages or generated summaries to a user who lacks permission to see the underlying source. This seems straightforward until a model produces an answer that blends material from several repositories. Retrieval permissions and output controls must be designed together.</p><p>Actions need separate authority. Searching a knowledge base, drafting a suggested revision, updating an asset, changing a workflow state, and recording approval are distinct permissions. Consequential state changes should require explicit action by an authorized person. The system may prepare the work, but it should not infer approval from silence or a reviewer opening a file.</p><p>Audit records should show the user, system version, sources retrieved, recommendation, human disposition, and any override rationale. They should preserve enough information to reconstruct a decision without retaining unnecessary sensitive data indefinitely.</p><h3>Evaluate claims not only answers</h3><p>Testing with generic question-answer benchmarks will not show whether the system performs well in review. Build an evaluation set from realistic assets and known issues, with qualified reviewers establishing the expected findings and recording disagreements.</p><p>The set should include unsupported claims, partially supported claims, correct claims with difficult citations, outdated labels, conflicting references, comparative language, omissions, and assets whose visual presentation changes the implied message. It should cover different products, markets, and channels.</p><p>Measure at least two kinds of error. A missed material issue can allow problematic content to progress. An excessive false alarm can consume reviewer time and lead users to ignore the system. Severity matters; missing a minor style issue is different from missing a material safety or efficacy claim.</p><p>Evaluation should examine evidence quality. Does the cited passage actually support the finding? Can the reviewer locate it? Was a newer source available? If the system identifies a real issue for the wrong reason, the conclusion may not be dependable after a source change.</p><p>Testing should also compare the AI-supported process with the existing one: review time, rework, reviewer agreement, quality of documented decisions, and issues found after approval. A tool that speeds the first pass but doubles later corrections has a different value proposition from the demonstration.</p><p>Consider a hypothetical oncology asset whose headline says a medicine improves survival, while the cited passage reports progression-free survival. The words may sound close to a general language model; the clinical endpoints are different. A reviewer needs the exact statement, population, endpoint, comparator, and source limitation in view. An automated finding that merely reports “citation present” would miss the issue. This kind of endpoint mismatch belongs in the evaluation set alongside outright fabricated references and unsupported numerical claims.</p><h3>Human review needs a useful interface</h3><p>“Human in the loop” is not enough. Reviewers need an interface that shows the claim in context, the relevant source passage, the system’s reasoning in a concise form, and the uncertainty or conflicting evidence. They should be able to accept, reject, revise, or escalate each finding and record a reason when appropriate.</p><p>The interface should not bury the asset under hundreds of low-value flags. Findings can be prioritized by materiality and confidence, but the prioritization itself needs evaluation. A system that hides low-confidence issues may miss novel problems; a system that displays everything may exhaust users.</p><p>Medical, legal, and regulatory reviewers bring different expertise. The workflow should route a scientific evidence question to the appropriate medical reviewer, a legal interpretation to counsel, and a product-labeling issue to regulatory or the designated review function. The AI can help organize those issues, but it should not flatten them into a single automated verdict.</p><p>Disagreement between qualified reviewers is useful data. It may indicate an ambiguous claim, unclear internal policy, or a gap in the evidence. The system should preserve and surface those patterns rather than treat one person’s disposition as unquestionable ground truth for future training.</p><h3>Change control covers more than the model</h3><p>The model can change. So can prompts, retrieval settings, source libraries, policy rules, document parsers, and the workflow. Each can alter findings. Version the complete review configuration and test material changes against a representative evaluation set before production. The team should know which changes are routine, which require additional clinical or regulatory assessment, and which could affect prior approved content.</p><p>A new label is an obvious event. Less obvious changes include a retrieval index rebuilt with different chunking, a prompt that changes how comparative claims are flagged, or an agent given a new ability to edit an asset. Release notes should describe user-relevant behavior, not only software components.</p><p>Monitoring should track missed issues reported later, reviewer overrides, false-positive burden, source failures, and variation among product teams. A rise in overrides may mean the model has degraded, the library is out of date, or users are applying a different standard. The investigation needs domain experts and technical staff together.</p><p>NIST’s generative AI profile provides cross-sector risk considerations. It is a useful organizing resource, but the application still needs local evidence about the failure modes that matter in its particular content process. [4]</p><h3>Distinguish support from approval</h3><p>The architecture should make one boundary unmistakable. AI may prepare a review, identify possible issues, and suggest revisions. Qualified people remain responsible for the final disposition under the organization’s procedures.</p><p>This boundary should be visible in the product. A generated “approved” badge or a green overall score can imply a decision even if a disclaimer says otherwise. The final record should name the approvers and show their action. An agent’s recommendation is part of the evidence they considered, not a substitute for their approval.</p><p>The organization should also define when AI support is inappropriate. A novel clinical claim, a major safety change, a complex legal dispute, or a new market may require a different review route. Automation should reduce repetitive work without making exceptional cases look routine.</p><h3>A practical first deployment</h3><p>Begin with one content category, one product or franchise, and a bounded task such as claim extraction and source linking. Build an authoritative library, create a reviewer-adjudicated evaluation set, and run the system alongside the existing process.</p><p>At first, reviewers should see findings without allowing the system to change workflow state. Record which findings saved time, which were misleading, and which material issues it missed. Improve the source and data process before adding more agents. Only then consider extending the system to additional tasks, markets, and products.</p><p>Expansion should follow evidence that the system resolves a documented review bottleneck and preserves an adequate record of its findings. The decisive value of AI in review may be less time spent searching and more time spent on judgment. A reviewer who can see the relevant label, source, and claim context quickly is better equipped to make a defensible decision. That benefit is credible only if the system’s limits remain visible.</p><p>The pilot should also include the people who create content. If authors repeatedly submit the same unsupported claim, the organization may need better guidance or templates upstream. If the system flags acceptable claims because its source library is incomplete, reviewers should not be expected to compensate forever. A good implementation uses observed review patterns to improve the surrounding process, not merely to tune the model. That is where much of the lasting return may come from across a large product portfolio.</p><h3>The architecture in one view</h3><p>A production review system should contain five connected layers:</p><p>1. <strong>Intake:</strong> asset, context, product, market, audience, channel, and version.</p><p>2. <strong>Evidence:</strong> controlled, permission-aware, versioned authoritative sources.</p><p>3. <strong>Analysis:</strong> bounded tasks that extract, compare, cite, and abstain when uncertain.</p><p>4. <strong>Disposition:</strong> qualified reviewer decisions, escalation, and documented overrides.</p><p>5. <strong>Learning:</strong> evaluation, monitoring, incident response, and controlled changes.</p><p>Each layer should be testable. A failure in one should be identifiable rather than concealed by an elegant final summary. The implementation should be judged by the quality and efficiency of the resulting review. A reviewer needs to locate the relevant evidence, understand the issue, and make a decision that another qualified person can reconstruct.</p><p>Reviewer disagreement should remain visible in that record. It can inform controlled improvements to retrieval, policy, and interface design; it should not become an automatic instruction to change the system. The architecture succeeds when it gives expertise more useful evidence to work with and preserves the authority of the people responsible for disposition.</p><h3>Sources</h3><p>[1] Amazon Web Services. <em>Medical Legal Regulatory Review Orchestration with AI Agents on AWS</em> (June 11, 2026). <a href="https://aws.amazon.com/blogs/industries/medical-legal-regulatory-review-orchestration-with-ai-agents-on-aws/">Source</a></p><p>[2] U.S. Food and Drug Administration. <em>Office of Prescription Drug Promotion.</em> <a href="https://www.fda.gov/about-fda/cder-offices-and-divisions/office-prescription-drug-promotion-opdp">Source</a></p><p>[3] U.S. Food and Drug Administration. <em>Prescription Drug Advertising and Promotional Labeling.</em> <a href="https://www.fda.gov/drugs/surveillance-post-drug-approval-activities/prescription-drug-advertising-and-promotional-labeling">Source</a></p><p>[4] National Institute of Standards and Technology. <em>AI Risk Management Framework: Generative AI Profile</em> (2024). <a href="https://www.nist.gov/publications/artificial-intelligence-risk-management-framework-generative-artificial-intelligence">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a8905950e6c5" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Data Decision Log That Life Sciences Partnerships Need]]></title>
            <link>https://medium.com/@yadav_ashish/the-data-decision-log-that-life-sciences-partnerships-need-551a4eef3499?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/551a4eef3499</guid>
            <category><![CDATA[partnerships]]></category>
            <category><![CDATA[clinical-development]]></category>
            <category><![CDATA[life-sciences]]></category>
            <category><![CDATA[companion-diagnostic]]></category>
            <category><![CDATA[data-governance]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Tue, 20 Oct 2026 23:36:01 GMT</pubDate>
            <atom:updated>2026-10-20T23:36:01.651Z</atom:updated>
            <content:encoded><![CDATA[<p>A laboratory sends a corrected biomarker report after a study site has acted on the original classification. The corrected record reaches the sponsor’s database, but the eligibility list and an earlier program report still carry the first result. Each system has a record of its own activity. The partnership lacks a shared account of the decision and its consequences.</p><p>This hypothetical example shows a gap that access policies and data dictionaries cannot close on their own. The teams need to agree which interpretation governs, who has authority to decide, which outputs are affected, and what must happen next. A record marked “resolved” is inadequate if the correction has not reached the people using it.</p><p>In my work across therapeutic development, diagnostics, and partnerships, the handoff between organizations has often required as much attention as the individual deliverable. A data decision log provides a practical record for consequential interpretations that cross those boundaries. It links the question, evidence, decision owner, implementation, and conditions for reconsideration.</p><p>The log belongs alongside established clinical data and quality processes. It should make a cross-partner decision easier to inspect without becoming a second source system or an informal substitute for controlled approval.</p><h3>A data dictionary does not resolve every dispute</h3><p>A dictionary might define “sample collected,” “assay valid,” or “site activated.” In practice, a result can be more complicated. A specimen may have been collected during routine care before trial consent, processed after a protocol amendment, or tested with a version of the assay that later changes. The data field has a definition, but the team still must decide how that record affects eligibility, analysis, or a quality investigation.</p><p>The decision log should not replace the dictionary, protocol, or controlled procedures. It should link to them and record how the team resolved a specific ambiguity. A useful entry states the question, affected data, applicable documents and versions, competing interpretations, decision authority, chosen interpretation, effective date, and downstream consequences. It should distinguish a temporary operational rule from a formal change requiring approval.</p><p>The log should have a narrow scope. Routine corrections belong in the source system and its audit trail. A decision log is for interpretations that can alter an important measure, patient selection, evidence package, or external commitment. If every spelling correction becomes a governance meeting, the mechanism will be ignored.</p><p>The first challenge is agreeing on what counts as consequential. A disagreement over one record may be material if it changes a patient classification near a biomarker threshold. A discrepancy across hundreds of records may be less material if it does not affect the intended analysis. The team should define materiality by decision impact, not record count alone.</p><p>Roche’s May 2026 agreement to acquire PathAI illustrates the industry’s interest in bringing digital pathology, biomarker work, and companion diagnostics together. The public announcement describes that direction, not the performance of a particular joint development program. In a collaboration using those capabilities, an interpretation can cross therapeutic, laboratory, and software boundaries. A shared decision record is one way to keep the applicable evidence and authority visible at each handoff. [4]</p><h3>Follow the information from source to action</h3><p>Consider a hypothetical program using a biomarker test to determine study eligibility. A site collects tissue, a courier transports it, a laboratory receives and assesses it, an assay produces a score, and a clinical system receives the reported classification. The study team then decides whether the person can enroll.</p><p>At each handoff, meaning can change. “Received” may refer to arrival at a shipping hub or accession at the laboratory. A test run can be technically complete but invalid under the quality criteria. A revised report may supersede a preliminary result after the site has already acted. A specimen identifier may be corrected after the result is transferred.</p><p>Map each point where a data value informs a decision. The map should identify the authoritative system, timestamp, version, and responsible person or function. It should state whether a downstream team receives an update when the source changes. A data pipeline that transfers the first report but not an amended report can be technically reliable while clinically wrong.</p><p>The decision log records exceptions to the agreed rules. If a site asks whether a preliminary result can support screening, the answer should not live only in an email between two individuals. The team needs a controlled interpretation, its scope, and a path for notifying everyone whose workflow depends on it.</p><p>The same structure applies beyond diagnostics. A manufacturing partner may report a batch status using its own milestones. A CRO may call a site active when contracts are complete, while the sponsor means ready to enroll. A digital health provider may call a measurement complete when uploaded, although quality checks later exclude it. The words are familiar; the operational states differ.</p><h3>Give each decision a clear owner</h3><p>Partnership agreements name organizations, yet a data disagreement needs a person or function empowered to resolve it. Technical staff may identify an issue without authority to change a clinical rule. Clinical staff may understand the consequence without knowing the source-system behavior. Regulatory or quality teams may need to approve a controlled change rather than merely be informed afterward.</p><p>Three roles need to be explicit. The issue owner investigates and assembles the facts. The decision owner accepts the interpretation within a specified scope. The implementation owner updates systems, documents, and affected teams. These can be different people. A single accountable name for each role avoids an unresolved issue circulating across a committee.</p><p>Escalation should reflect risk and timing. A question that could change enrollment tomorrow may need a same-day route. A nonurgent reconciliation rule for a future analysis can be reviewed in a scheduled forum. The operating model should state who can make an interim decision, how it is recorded, and when formal approval is required.</p><p>Cross-organization contracts should support this process. They can require timely notice of corrected records, access to relevant audit history, cooperation in root-cause investigation, and agreed turnaround for material issues. The contract need not anticipate every ambiguity. It should make it possible to resolve one without arguing first about who is allowed to see the evidence.</p><p>FDA’s electronic source data and electronic systems guidance provide the regulatory context for reliable and traceable clinical records. The decision log proposed here is an operating recommendation; those documents do not prescribe this particular format. It should link to established records and procedures rather than replace them. [1, 2]</p><h3>Record what was known at the time</h3><p>A decision made in March may look questionable in June if the underlying data were later corrected. The log should preserve what information was available at the decision time. It should link the decision to source versions and identify later updates. This allows the team to distinguish a reasonable decision under the evidence then available from a process failure that should have been detected.</p><p>Time is not one field. Source creation, clinical event, laboratory receipt, system entry, approval, transmission, and effective dates can differ. A record that arrived in an analysis environment on Tuesday may describe a patient event from the prior month. Governance should specify which timestamp answers which question.</p><p>If a revised assay report changes a classification, the team should be able to identify the original report, revised report, reason for correction, recipients, and actions taken under each. Simply overwriting the earlier value destroys the chain needed for clinical and quality review.</p><p>Version control extends to reference information. Protocol amendments, assay instructions, case report forms, endpoint definitions, and data transformations may change. The log should state the version governing a decision. Without this, a team can apply today’s rule to yesterday’s record and present an apparently consistent but historically inaccurate result.</p><p>This is particularly important when different partners work on different update cycles. One partner may deploy a data mapping weekly while another changes a controlled document quarterly. A common calendar of changes and effective dates reduces the risk of silent divergence.</p><h3>Separate correction from reinterpretation</h3><p>If a value was entered incorrectly and the source can be verified, a correction may follow an established data management process. If the source is accurate but the team disagrees about what it means, the issue is interpretive. The distinction affects approval, traceability, and communication.</p><p>Suppose a laboratory reports a valid numerical score but the sponsor’s integration applies an outdated cutoff. The source score may be correct; the derived classification is not. Fixing a mapping may require assessing every affected record and any actions taken on the previous classification. A decision log can capture scope and remediation, while the technical audit trail captures the actual correction.</p><p>Now suppose experts disagree over whether a borderline specimen meets an established quality criterion. That may require a scientific and quality determination, not a database patch. The outcome and rationale should be documented at the level appropriate to the program. A script that forces the preferred classification would conceal the underlying judgment.</p><p>The issue owner should identify whether the problem is a source error or a disputed interpretation. This prevents meetings from jumping immediately to an IT fix for a clinical ambiguity or from escalating a simple source correction into a new policy debate.</p><h3>Design the log for use not display</h3><p>A practical log needs a small number of required fields and links to authoritative evidence. It should support search by program, dataset, decision type, and status. Sensitive details should remain in the appropriate controlled system, with access governed by role. The log can point to records without copying confidential patient or partner information into a broad collaboration tool.</p><p>The log needs an “affected outputs” field. If a decision changes a dashboard, eligibility list, analysis dataset, regulatory figure, or partner report, those artifacts should be identified and updated or clearly marked. A resolved issue is not truly resolved while downstream reports still use the old rule.</p><p>The log should have a review date where uncertainty remains. An interim interpretation may be reasonable while awaiting assay data or a formal protocol change. It should not become permanent simply because the team forgot its temporary status.</p><p>The organization should also avoid using the log as a substitute for formal quality processes. An adverse event, deviation, complaint, or controlled document change may have a prescribed route. The log can link to that route and show the cross-partner decision, but it should not create a competing unofficial record.</p><h3>Measure whether it improves the partnership</h3><p>Counting log entries is a weak measure. A rise in entries could mean better detection or a deteriorating data process. Track time from issue identification to a decision, unresolved material issues at key milestones, repeated disputes over the same definition, downstream corrections, and the proportion of decisions communicated to all affected partners.</p><p>Periodically sample entries for quality. Could an independent reviewer understand the question, evidence, authority, and action? Are temporary decisions revisited? Did the resolution reach systems and people who depend on it? These checks reveal whether the log is a living control or a repository of meeting minutes.</p><p>Patterns can expose structural problems. If many issues concern site status, the partners may need a better shared state model. If amended laboratory reports repeatedly fail to reach sites, a feed and notification process needs repair. The log’s value lies partly in identifying root causes that a series of one-off fixes would hide.</p><p>This can improve relationship quality. Partners are less likely to interpret every disagreement as poor performance when there is a fair process for evidence and resolution. Accountability becomes clearer without assuming bad intent. The discussions focus on the patient or program decision affected by the data.</p><h3>A ninety day introduction</h3><p>Introduce the log in one collaboration and two or three decision types. Start with a short workshop to map the source-to-decision chain. Agree on terms that already cause disagreement, identify decision owners, and set escalation times. Use an existing controlled tool where possible rather than buying software first.</p><p>During the first month, record only material ambiguities and review the format weekly. In the second, assess whether decisions reach downstream systems and teams. In the third, review recurring themes and decide which definitions or data contracts should be changed. This sequence produces a practical operating process, not another governance policy that people learn about after an incident.</p><p>Test the process with a realistic example before relying on it. Ask how the team would handle a corrected biomarker result after a site acted on the original report. If nobody can identify the owner, recipients, and affected records, refine the route. The exercise is valuable even if that exact event never occurs.</p><p>The log does not eliminate judgment. It makes judgment inspectable and actionable across organizations. That is a useful standard for data governance in a partnership: the right people can see the evidence, understand the interpretation, implement it consistently, and revisit it when new information arrives.</p><h3>When the data decision affects a submission</h3><p>The log becomes especially valuable when a discrepancy is found after an analysis or document has been assembled. The team needs to identify which outputs use the affected interpretation and whether the change is material to a conclusion. A line in an issue tracker that says “resolved” does not tell a reviewer whether tables, figures, listings, or narrative statements were assessed.</p><p>The resolution needs a short impact assessment: affected records and time period, prior and corrected rule, outputs reviewed, decision maker, and disposition. If no output changes, record why. If an output changes, preserve the earlier version and the approval trail. This provides a defensible history without turning every correction into a crisis.</p><p>The same discipline helps when an external partner changes its system. A new software release may alter a field name or export format while leaving the displayed values apparently familiar. A regression check should compare representative records and derived measures. If differences arise, the decision log can connect the technical finding to the clinical or regulatory choice it affects.</p><p>At a submission milestone, the question is whether the team can account for the conclusions it presents. A timely record of interpretation and implementation helps establish that account. It also preserves the reasoning for colleagues who join the program later and need to understand why an apparently simple field is governed by a particular rule.</p><h3>Sources</h3><p>[1] U.S. Food and Drug Administration. <em>Electronic Source Data in Clinical Investigations</em> (2013). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-source-data-clinical-investigations">Source</a></p><p>[2] U.S. Food and Drug Administration. <em>Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers</em> (final guidance, October 2024). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions">Source</a></p><p>[3] Clinical Data Interchange Standards Consortium. <em>Foundational standards.</em> <a href="https://www.cdisc.org/standards/foundational">Source</a></p><p>[4] Roche. Definitive merger agreement to acquire PathAI (May 7, 2026). <a href="https://www.roche.com/media/releases/med-cor-2026-05-07">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=551a4eef3499" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What AI Validation in Digital Health Looks Like After the Demo]]></title>
            <link>https://medium.com/@yadav_ashish/what-ai-validation-in-digital-health-looks-like-after-the-demo-f99002768f98?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/f99002768f98</guid>
            <category><![CDATA[healthcare-ai]]></category>
            <category><![CDATA[medical-devices]]></category>
            <category><![CDATA[digital-health]]></category>
            <category><![CDATA[product-development]]></category>
            <category><![CDATA[clinical-validation]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Thu, 15 Oct 2026 13:01:03 GMT</pubDate>
            <atom:updated>2026-10-15T13:01:03.480Z</atom:updated>
            <content:encoded><![CDATA[<p>A convincing demonstration is often the easiest part of a digital health AI product to understand. A clinician enters a case, the system returns a plausible output, and the team can see a possible improvement in its workflow. The difficult work begins when that result becomes a product claim.</p><p>The claim determines the evidence. An assistant that prepares a draft note, a tool that prioritizes records for clinical review, and a system that recommends intervention may use similar technology. They ask users to rely on it in different ways, with different consequences when it fails. Validation has to address those differences explicitly.</p><p>Across medical devices, diagnostics, clinical programs, and digital health, I have worked with the relationship between intended use and evidence. The same discipline applies to AI: define the task, identify the relevant population and setting, and establish what the output allows a user to do. A strong retrospective metric is useful evidence within that assessment, but it cannot settle the release decision on its own.</p><p>For product teams and investors, the practical question is whether the system has been evaluated under the conditions that will determine its value after deployment. That includes incomplete inputs, ordinary users, competing workload, and a workable response when the product is wrong.</p><p>Microsoft’s documentation for Dragon Copilot describes draft clinical documentation generated from recordings for clinician review. A hospital assessing an implementation should examine whether clinically important information survives into the draft and whether reviewers detect omissions or unsupported additions. The product documentation describes capabilities; local evaluation must establish their performance in the proposed setting. The evaluation unit is the completed clinical record and the review needed to produce it, rather than the generated text alone. [5]</p><h3>A model result is not a product claim</h3><p>Suppose an AI tool reviews a patient’s history and flags a possible need for follow-up. A development team reports 92% accuracy on a test set. That number leaves crucial questions unanswered.</p><p>What counted as a correct recommendation? Who established the reference? Was the test set drawn from the same health systems used in training? Were uncertain cases excluded? How common is the condition in the intended setting? What happens when the system is wrong?</p><p>Accuracy alone can conceal a poor product. If the event is uncommon, a system that rarely flags anyone can achieve a high overall score. If false negatives delay needed care, sensitivity may matter greatly. If false positives overwhelm a clinical team, positive predictive value and the volume of reviews matter. Calibration matters when users see a probability and are expected to act at a threshold.</p><p>The product’s claim must be stated in terms of the actual user and workflow. “AI identifies risk” is too broad. Does it prioritize records for qualified review, recommend a specific action, or trigger an automatic message? Is the user a specialist, primary care clinician, nurse, or patient? At what point in the encounter does the output arrive? Is it intended for triage, diagnosis, monitoring, or administration?</p><p>Each answer changes the validation design. A retrospective model metric cannot establish that a tool makes a clinical workflow better.</p><h3>Map the path from input to action</h3><p>The validation team should map the complete sequence before choosing an evaluation endpoint: input arrives, the system checks whether it is usable, the model produces an output, the interface displays it, a person interprets it, and an action follows. The sequence should also include what happens when data are missing, the model cannot process a case, or the user disagrees.</p><p>For example, a digital health tool may estimate deterioration risk from remotely collected measures. Its performance depends on whether patients use the device consistently, whether the signal is captured correctly, whether connectivity delays the data, whether staff review alerts in time, and whether an appropriate response is available. A strong algorithm cannot compensate for an alert arriving after the actionable window.</p><p>The product team should distinguish analytical performance from clinical and operational performance. The model may classify a pattern well in a dataset. The deployed system may fail because a sensor is worn incorrectly, a field is mapped differently, a notification is buried, or the clinical team receives too many alerts.</p><p>FDA’s guidance on digital health technologies used for remote data acquisition in clinical investigations addresses the selection, verification, validation, and use of such technologies in trials. Not every commercial digital health product has the same regulatory status or use, but the emphasis on fit for purpose and the full data pathway is broadly useful. [3]</p><p>A validation plan should be designed around the weakest meaningful link in that pathway, not only around the easiest metric to calculate.</p><h3>Separate three kinds of evidence</h3><p>First, the team needs evidence that the technical system functions as specified. Can it accept the intended inputs, identify out-of-range or missing data, preserve records, control access, and deliver an output within the required time? Can a user reproduce or investigate a result?</p><p>Second, it needs evidence that the output is valid for the intended population and decision. That means a credible reference standard, appropriate separation of development and evaluation data, performance measures suited to the use, and examination of variation across relevant groups and settings.</p><p>Third, it needs evidence that the product works in the actual workflow. Do intended users understand the output? Do they follow it appropriately, challenge it when needed, and avoid over-reliance? Does the product improve an outcome that matters without creating an unacceptable burden elsewhere?</p><p>These three layers are related but not interchangeable. A device can be technically reliable and clinically unhelpful. A model can perform well in a held-out dataset and be difficult for a clinician to use. A workflow can feel efficient while quietly missing cases in a population that was poorly represented during development.</p><p>The evidence plan should identify which layer each study or test addresses. That prevents a usability demonstration from being cited as proof of clinical effectiveness or a retrospective accuracy estimate from being used to imply workflow benefit.</p><h3>Evaluate the data that the product will actually see</h3><p>Development datasets are often cleaner than deployment data. A trial may have trained personnel, defined collection windows, and strong follow-up. Routine care can involve missing records, unusual cases, device variation, language differences, and inconsistent practice.</p><p>The validation dataset should represent the intended environment, including the hard cases. If the system will be used at several hospitals, it needs evaluation across those hospitals or a justified plan for understanding between-site variation. If different devices or scanners produce inputs, their effect should be measured. If the product will be used in children or older adults, the evidence should address those populations rather than assume the average result transfers.</p><p>Temporal separation is also important. A random split can put near-duplicate records or information from the same care pattern on both sides of evaluation. An out-of-time assessment can reveal whether performance holds after practice or data systems change. External evaluation can test whether the system has learned a generalizable relationship or merely the habits of one institution.</p><p>I pay particular attention to data availability. A final diagnosis, corrected laboratory value, or completed note may appear in a retrospective dataset even though it was unknown when the product would have made its recommendation. A validation exercise that uses such information evaluates a different product from the one that will be deployed.</p><p>The dataset documentation should therefore say when each input becomes available, how it is transformed, why a record is excluded, and which versions of instruments or software contributed data.</p><h3>Average performance can conceal unequal performance</h3><p>A single overall number rarely explains whether an AI health product is dependable. Performance may differ by care setting, age, sex, race or ethnicity where appropriately measured, disease severity, equipment, language, geography, or the quality of underlying records.</p><p>Subgroup analysis requires care. Small samples produce unstable estimates, and a long list of comparisons can invite false conclusions. The answer is not to avoid the question. The team should identify the differences most plausible and consequential for the intended use, seek enough data to assess them, and report uncertainty honestly.</p><p>Missingness itself may be uneven. A system can seem to work well among people with complete records while silently excluding those whose care is fragmented across institutions. The product’s effective coverage should be reported alongside its conditional performance among processed cases.</p><p>The clinical consequence should guide attention. If a missed case could delay treatment, the team should examine whether misses cluster in a particular setting. If false alarms create unnecessary procedures, it should examine where those alarms arise. An overall metric can hide the part of the product most relevant to safety and access.</p><p>The release decision can accommodate uncertainty, provided the team states its limits and manages them. Evidence supporting one population or setting should not be presented as assurance for another without a justified assessment.</p><h3>Test how people use the output</h3><p>“Human oversight” is often treated as a safeguard. It can also be a weak point if the human is given too little information or too much work. A user needs to understand what the output means, which inputs were used, and when the system may be unreliable. A risk score without a clear time horizon or interpretation can be read in several ways. A generated summary that cites a source may create unwarranted confidence if the cited material supports only part of the statement.</p><p>Usability work should observe the intended users completing realistic tasks, including ambiguous cases, missing data, and disagreements with the model. What do they do when the system abstains? Can they find the original evidence? Do they notice a warning? Does an alert change the decision appropriately, or does it lead to automation bias?</p><p>The evaluation should also consider workload. A system that identifies more true cases but triples manual review time may still be worthwhile in a high-stakes setting. The tradeoff should be measured and accepted deliberately. If the same system is deployed in an understaffed setting, its practical value may differ.</p><p>Interface choices shape behavior. A recommendation placed as the first item in a queue can become a default. A hidden confidence interval may be ignored. A requirement to document an override can discourage justified disagreement. Product design is part of the validation target.</p><h3>Monitor the deployed system as a whole</h3><p>After launch, performance may change even if the model code does not. New patients enter the system. Clinical practice evolves. A laboratory changes a method. A hospital updates its electronic record. A device firmware release alters the input signal. Users develop shortcuts.</p><p>Monitoring should follow the failure modes identified before deployment. Track input quality and coverage, output distribution, review and override patterns, clinical outcomes where available, complaints, and differences by setting. The team should be able to distinguish a data pipeline error from a real change in the population or workflow.</p><p>NIST’s AI Risk Management Framework includes postdeployment monitoring, user input, override, incident response, recovery, and change management. FDA’s draft lifecycle guidance for AI-enabled device software functions also discusses lifecycle risk and performance monitoring. Those documents are useful references, but a product still needs its own specific thresholds and response owners. [1, 4]</p><p>What triggers investigation? When should use be narrowed or paused? Who has authority to act? How will affected users learn about an issue? How are corrections tested before release? Monitoring without these decisions is a collection of charts, not a control system.</p><p>There should also be a way to learn from near misses. A clinician’s override may reveal a case the model did not understand. It may also reflect a misunderstanding of the interface. The organization should investigate patterns rather than treating every override as either a human error or a model error.</p><h3>Changes require evidence not just release notes</h3><p>Digital products change frequently. A model update, prompt revision, input source change, user-interface redesign, or new integration can alter the product’s behavior. The change-control process should connect each change to intended use, risk, validation evidence, and monitoring.</p><p>Not every change requires the same work. A spelling correction has a different effect from changing a decision threshold. But a small-looking technical change can be consequential if it affects the output for a vulnerable group or changes when a clinician sees an alert.</p><p>FDA’s guidance on predetermined change control plans for AI-enabled device software functions offers a specific regulatory mechanism for certain anticipated modifications when an authorized plan is in place. It should not be flattened into a claim that AI devices may update freely. The practical discipline is to identify likely changes, describe their boundaries and assessment methods, and preserve the evidence that the modified product remains appropriate. [2]</p><p>For products outside that particular pathway, the same operational question remains: how will the team know that the product after an update is still the product it evaluated?</p><h3>A release decision should be explicit</h3><p>The release review should resolve the following questions:</p><p>1. What exact use has been evaluated, and which uses remain outside the evidence?</p><p>2. What data, population, sites, devices, and users were represented?</p><p>3. Which errors would matter most, and what did testing show about them?</p><p>4. Can intended users interpret, challenge, and act on the output?</p><p>5. What will be monitored, who responds, and when can use be paused?</p><p>6. Which future changes require additional evaluation or regulatory assessment?</p><p>The answer may be to deploy to a limited setting, collect prospective evidence, and expand only when the results justify it. That can be a stronger product strategy than either indefinitely delaying use or launching everywhere on the strength of a demonstration.</p><p>The demonstration is still useful. It helps people see a possible workflow and ask better questions. Validation begins when the team turns that possibility into a defined claim, tests it against the conditions of use, and accepts responsibility for what happens afterward.</p><p>A release decision should identify what the evidence supports today and what remains to be established. That gives the team a credible basis for controlled use, further evaluation, and expansion. The demonstration introduces a possibility; the validation record explains why a particular product can be used in a particular setting.</p><h3>Sources</h3><p>[1] U.S. Food and Drug Administration. <em>Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations</em> (draft guidance, 2025). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing">Source</a></p><p>[2] U.S. Food and Drug Administration. <em>Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions</em> (final guidance, 2025). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence">Source</a></p><p>[3] U.S. Food and Drug Administration. <em>Digital Health Technologies for Remote Data Acquisition in Clinical Investigations</em> (final guidance, 2023). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations">Source</a></p><p>[4] National Institute of Standards and Technology. <em>AI Risk Management Framework Core.</em> <a href="https://airc.nist.gov/airmf-resources/airmf/5-sec-core/">Source</a></p><p>[5] Microsoft. What is Microsoft Dragon Copilot (physicians)? <a href="https://learn.microsoft.com/en-us/industry/healthcare/dragon-copilot/about/">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f99002768f98" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Hidden Data Contract Between a Sponsor and a CRO]]></title>
            <link>https://medium.com/@yadav_ashish/the-hidden-data-contract-between-a-sponsor-and-a-cro-fe80ed922935?source=rss-7dc613c7b115------2</link>
            <guid isPermaLink="false">https://medium.com/p/fe80ed922935</guid>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[data-governance]]></category>
            <category><![CDATA[data-engineering]]></category>
            <category><![CDATA[clinical-data]]></category>
            <category><![CDATA[life-sciences]]></category>
            <dc:creator><![CDATA[Ashish Yadav]]></dc:creator>
            <pubDate>Wed, 14 Oct 2026 02:23:09 GMT</pubDate>
            <atom:updated>2026-10-14T02:32:22.446Z</atom:updated>
            <content:encoded><![CDATA[<p>A clinical data feed can arrive on time, pass every technical check, and still leave a sponsor unable to explain an enrollment trend. The failure may sit in an ordinary field such as “screened”: one team counts consented patients, another includes molecular prescreening, and a third reports only records reviewed under the current protocol. The dashboard combines them as if they describe the same event.</p><p>In this illustrative situation, the transport specification has worked. The agreement about the data has not. File formats and delivery schedules establish how information moves; they do not establish what a measure represents, which corrections have been applied, or when a team could reasonably rely on it.</p><p>My experience across clinical development, diagnostics, and regulated product programs has made me attentive to these handoffs. A consequential number needs an agreed definition and an owner who can explain it. When a sponsor delegates data operations, that requirement travels with the work.</p><p>The data contract should therefore be treated as an operating agreement between the organizations. It connects the protocol, source systems, analytical use, and the process for resolving disagreement. The following examples are hypothetical; the proposed method is a practical way to keep clinical meaning intact as systems and studies change.</p><p>IQVIA’s December 2025 announcement with AWS describes an agentic platform for clinical trial execution, medical affairs, and healthcare analytics. That scope makes shared definitions important across several workflows. The announcement identifies an intended platform direction; it does not establish that every customer’s data contract is resolved. For a sponsor evaluating such services, the practical assessment should include whether operational terms retain their meaning across the partner’s systems and the sponsor’s own reporting. [6]</p><h3>The transport specification is only the first layer</h3><p>A conventional interface specification says that the sponsor will receive a site identifier, screening count, enrollment count, country, date, and status. It may specify a CSV, API, or database view, along with required fields and a delivery schedule. An automated check can confirm that the file arrived and that all fields have expected types.</p><p>Those controls catch important failures. They do not tell the sponsor whether the screening count includes prescreening, whether the date is the event date or the system-entry date, or whether a participant who changes sites is counted twice. A pipeline can be perfectly reliable at moving the wrong interpretation.</p><p>The next layer is semantic. Every material measure needs a plain-language definition, inclusion and exclusion rules, an authoritative source, and a version. If the measure is derived, the contract should explain the transformation. A user should know whether a number is a current operational estimate, a reviewed study record, or a submission-ready value.</p><p>The final layer is decision-specific. A weekly operational dashboard can tolerate some provisional data if it displays the limitations. A formal study report or external evidence package needs a different review state. A model used to rank sites may need historical snapshots showing what was available before a selection decision. Calling all three “clinical data” conceals different requirements.</p><p>The contract should therefore name its intended uses. A dataset suitable for one use should not automatically become the source for another because it happens to be in the platform.</p><h3>Define events not just fields</h3><p>Clinical development measures often look simple until someone asks when the event occurred. Consider a participant who signed consent, had a molecular test ordered, received a result, failed one criterion, was later rescreened under an amended protocol, and enrolled at another site.</p><p>How many screenings occurred? Which site gets credit for the enrollment? When did the participant become eligible? Which protocol version applies? The answer depends on the operational question. There may be legitimate reasons to represent more than one event, but a single “screened” column cannot carry the whole story.</p><p>Event-oriented data are often more useful than overwritten status fields. Preserve the underlying events with timestamps and context, then define the measures derived from them. If a status changes, retain the earlier state and the reason for correction. That allows an analyst to reproduce what a team knew on a particular date.</p><p>This matters acutely when data feed prediction. If a sponsor evaluates a model that was supposed to help choose sites before trial launch, the training data should reflect information available before that choice. A final enrollment value or later site-status update may improve retrospective model performance while being unusable at the intended decision point.</p><p>The data contract should distinguish event time from entry time and ingestion time. These can differ by days or weeks. A laboratory result may have a specimen collection date, receipt date, analysis date, report date, and date the study team saw it. The correct timestamp depends on the question.</p><p>An engineer should not have to infer that choice from a column name. The clinical and operational owners should decide it and document the rationale.</p><h3>Make provenance usable</h3><p>Provenance is often reduced to an identifier for the source system. That is a start. A consequential clinical value may also need a source record, instrument or assay version, protocol version, site, user or system that entered it, correction history, transformation rules, and review state.</p><p>The amount of detail retained should follow the use. A portfolio dashboard may not display all of it, but the organization should be able to trace a questioned value back through the chain. If a patient-selection model relies on a biomarker result, the model team should understand how that result was generated and whether the same method is used in the deployment population.</p><p>FDA’s electronic source data guidance addresses traceability and integrity in clinical investigations. Its 2024 electronic systems guidance also addresses trustworthy records and signatures. [1, 2] CDISC’s CDASH and SDTM standards support consistent collection and representation of study data. These are valuable foundations. They do not remove the need to decide how a sponsor’s operational measure is defined across its particular systems and partners. [3, 4]</p><p>It is possible to be technically conformant to a standard and still answer the wrong business question. A standardized dataset may preserve a clinical observation well but lack a timely operational event needed for site management. Conversely, an operational feed may support rapid intervention but require further reconciliation before it can support a formal analysis.</p><p>The contract should state which layer is authoritative for which decision. Otherwise the newest data source tends to win by convenience.</p><h3>Put data quality in context</h3><p>Data teams often report completeness, validity, consistency, and timeliness as percentages. Those metrics are helpful if they connect to a decision. A 95% complete field can be good or unacceptable depending on which 5% is missing.</p><p>Suppose biomarker results are missing disproportionately at smaller community sites. A trial matching model trained on available records may appear accurate while failing to identify eligible patients in those settings. A generic completeness score will not reveal the distribution. The quality assessment should examine missingness by site, population, collection method, and period when those differences matter.</p><p>Likewise, a date that arrives three days late may be acceptable for a monthly portfolio report and harmful for an urgent safety review. A corrected value may be suitable for a final analysis but should not be used as if it had informed an earlier operational decision.</p><p>Quality thresholds should be defined by use case. What is the consequence of a missing, delayed, duplicated, or misclassified value? Which errors can be tolerated temporarily with a visible warning? Which should block a report or trigger a manual review? Who decides that a dataset has reached the required state?</p><p>This avoids a common trap: polishing every field equally while leaving the few decision-critical measures ambiguous.</p><h3>A practical contract has owners on both sides</h3><p>A data contract cannot be owned solely by an integration engineer. The engineer can implement and test the interface. The meanings come from clinical operations, data management, medical, statistics, laboratories, and the people who use the output.</p><p>For each material data product, the sponsor and CRO should name a business or clinical owner, a technical owner, and a process for resolving disputes. Ownership should include the authority to approve a definition or change it. A long list of stakeholders without a decision maker is not ownership.</p><p>The contract also needs an escalation path. If two systems disagree about enrollment, who investigates? Which record is examined first? How quickly must a correction be communicated? Does a change flow into historical reports, or is it applied only going forward? What will downstream users see while the issue remains open?</p><p>These questions are easier to settle before a discrepancy reaches a governance meeting or submission deadline. A small number of worked examples can expose ambiguity early. Ask both parties to calculate the same measures from a few complicated participant journeys. If they reach different answers, the definition is not ready.</p><p>This is an area where a sponsor’s oversight role matters. Outsourcing data operations does not mean the sponsor can remain uncertain about how a consequential measure was produced. At the same time, the CRO needs enough clarity to implement the measure without receiving conflicting instructions from different sponsor functions.</p><h3>Version the meaning as well as the code</h3><p>Software teams are accustomed to versioning code and schemas. Clinical data teams should version definitions and decision rules with comparable care. A protocol amendment may change a screening criterion. A site activation definition may change when a new vendor takes over a step. A biomarker cutoff may be revised. A system migration may alter the event captured as enrollment. Each change can preserve the same field name while changing what the field represents.</p><p>The contract should record the effective date, reason, affected studies and records, backward compatibility, and treatment of historical data. If a dashboard shows trends across a change, it should indicate whether the measure is comparable on both sides. If not, the team may need to display a break in the series or recalculate from underlying events.</p><p>Versioning also matters for external partners. When a CRO updates its platform or a laboratory changes an assay, the sponsor needs advance notice of changes that affect its data product. A generic “vendor may update services” provision is not an adequate operating rule for a decision-critical feed.</p><p>The change process should allow the interface to evolve while protecting the comparability of the measures that users rely on.</p><h3>Test the contract with real questions</h3><p>Before production, the sponsor and CRO should test whether the feed answers the decisions it was commissioned to support. A schema checklist remains necessary, but it cannot establish that a derived measure is appropriate.</p><p>Can the sponsor reproduce last Tuesday’s enrollment dashboard, including the values that were later corrected? Can the CRO explain why two sites with similar counts received different performance assessments? Can a clinical reviewer trace a biomarker flag to its original report and assay version? Can an analyst identify which data were available before an AI-supported site-selection recommendation?</p><p>These tests use difficult records on purpose. They reveal whether the contract handles amendments, repeats, missing values, conflicting dates, delayed entries, and corrections. If it works only for a clean example, it is not ready for a clinical program.</p><p>Automated tests still have a role. They can check allowed values, referential integrity, uniqueness, expected volume, freshness, and unexpected shifts. But a semantic test should also confirm that a derived measure follows its approved definition. A sudden change may indicate a pipeline fault, a real clinical event, or a change in workflow; someone must be able to distinguish them.</p><p>The eventual report or model owner should participate in acceptance. The person who will rely on the data should be able to ask whether the output is suitable for the planned decision.</p><h3>AI raises the cost of ambiguity</h3><p>When a dashboard contains an unclear measure, a knowledgeable user may notice that it looks wrong. A model can combine ambiguous measures into a prediction that appears coherent. The ambiguity is harder to spot because it is distributed across many inputs.</p><p>For an AI use case, the contract should add a feature-level view: where each feature came from, how it was calculated, what timestamp defines availability, how missing values were handled, and whether its meaning changed during the training period. The organization should retain a reproducible snapshot of the data and transformations used for training and evaluation.</p><p>Deployment adds another requirement. Does the live feed mean the same thing as the development data? If a CRO changes its operational workflow or a sponsor adds sites in a new region, the model may receive values that satisfy the schema but have different clinical or operational meaning. Monitoring only statistical drift will not catch every semantic change. A change log and accountable owner are necessary.</p><p>The data contract needs to be settled before an AI product is described as ready to scale. The model cannot repair an unresolved disagreement about what an enrollment, event, specimen, or patient status represents.</p><h3>What the operating agreement should contain</h3><p>An effective sponsor–CRO data contract need not be an unwieldy manual. For each material feed and measure, it should provide:</p><p>1. <strong>Purpose and allowed uses:</strong> the decisions supported, the review state, and uses requiring a separate assessment.</p><p>2. <strong>Definitions:</strong> events, derivations, inclusion and exclusion rules, units, controlled terms, and worked examples.</p><p>3. <strong>Sources and timing:</strong> authoritative records, event and entry timestamps, refresh schedule, corrections, and historical snapshots.</p><p>4. <strong>Quality expectations:</strong> checks and thresholds tied to the consequence of an error.</p><p>5. <strong>Ownership:</strong> named decision makers for definitions, changes, discrepancies, and downstream communication.</p><p>6. <strong>Version and change process:</strong> notification, impact assessment, implementation, and treatment of historical data.</p><p>7. <strong>Traceability and access:</strong> the information needed to reconstruct a value and protect appropriate access.</p><p>8. <strong>Acceptance and monitoring:</strong> realistic test cases, ongoing checks, and a response when a feed fails.</p><p>The contract should be short enough to use and detailed enough to resolve a disagreement. Its purpose is to keep meaning stable while studies, systems, and partners change.</p><p>The practical test comes when the sponsor questions a number. Can both organizations reconstruct it using the same definition, source history, and effective rule? Can they identify what must change if the number is wrong? A contract that answers those questions gives the partnership a usable basis for oversight and analysis.</p><p>The same foundation supports AI, because training and deployment depend on consistent interpretation over time. The model team should receive an agreement about the information, not only access to a file.</p><h3>Sources</h3><p>[1] U.S. Food and Drug Administration. <em>Electronic Source Data in Clinical Investigations</em> (2013). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-source-data-clinical-investigations">Source</a></p><p>[2] U.S. Food and Drug Administration. <em>Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers</em> (2024). <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions">Source</a></p><p>[3] CDISC. <em>Foundational Standards</em> and <em>CDASH</em>. <a href="https://www.cdisc.org/standards/foundational">Source</a></p><p>[4] CDISC. <em>Study Data Tabulation Model (SDTM).</em> <a href="https://www.cdisc.org/standards/foundational/sdtm">Source</a></p><p>[5] U.S. Food and Drug Administration. <em>Study Data for Submission to CDER and CBER.</em> <a href="https://www.fda.gov/industry/study-data-standards-resources/study-data-submission-cder-and-cber">Source</a></p><p>[6] IQVIA. Strategic collaboration with AWS for an agentic AI platform (December 2, 2025). <a href="https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Announces-Strategic-Collaboration-with-AWS-Naming-AWS-as-Preferred-Agentic-Cloud-Provider-to-Power-Next-Generation-AI-Platform/default.aspx">Source</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fe80ed922935" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>